- 阻害剤
- 研究分野別
- PI3K/Akt/mTOR
- Epigenetics
- Methylation
- Immunology & Inflammation
- Protein Tyrosine Kinase
- Angiogenesis
- Apoptosis
- Autophagy
- ER stress & UPR
- JAK/STAT
- MAPK
- Cytoskeletal Signaling
- Cell Cycle
- TGF-beta/Smad
- 化合物ライブラリー
- 抗体
- 新製品
- お問い合わせ
BMS-754807
BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met (c-Met), Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.
CAS No. 1001350-96-4
文献中Selleckの製品使用例（51）
製品安全説明書
現在のバッチを見る：
純度：
99.72%
99.72
BMS-754807関連製品
シグナル伝達経路
IGF-1R阻害剤の選択性比較
Cell Data
| Cell Lines | Assay Type | Concentration | Incubation Time | 活性情報 | PMID |
|---|---|---|---|---|---|
| M109 | Growth inhibitory assay | ~5 μM | IC50=1.055 μM | 19996272 | |
| HCT116 | Growth inhibitory assay | ~5 μM | IC50=0.852 μM | 19996272 | |
| DU4475 2.431 | Growth inhibitory assay | ~5 μM | IC50=2.431 μM | 19996272 | |
| H526 0.044 | Growth inhibitory assay | ~5 μM | IC50=0.044 μM | 19996272 | |
| HT1080/S | Growth inhibitory assay | ~5 μM | IC50=0.531 μM | 19996272 | |
| MDA-MB-231T | Growth inhibitory assay | ~5 μM | IC50>5.00 μM | 19996272 | |
| H209 | Growth inhibitory assay | ~5 μM | IC50=1.193 μM | 19996272 | |
| SW-684 | Growth inhibitory assay | ~5 μM | IC50>5.00 μM | 19996272 | |
| MDA-MB-231 | Growth inhibitory assay | ~5 μM | IC50=1.648 μM | 19996272 | |
| Calu-6 | Growth inhibitory assay | ~5 μM | IC50>5.00 μM | 19996272 | |
| SW1990 | Growth inhibitory assay | ~5 μM | IC50=0.826 μM | 19996272 | |
| MDA-MB-468 | Growth inhibitory assay | ~5 μM | IC50=0.504 μM | 19996272 | |
| H1299 | Growth inhibitory assay | ~5 μM | IC50>5.00 μM | 19996272 | |
| SU.86.86 | Growth inhibitory assay | ~5 μM | IC50=2.672 μM | 19996272 | |
| JJN3 | Growth inhibitory assay | ~5 μM | IC50=2.433 μM | 19996272 | |
| NCI-H383 | Growth inhibitory assay | ~5 μM | IC50>5.00 μM | 19996272 | |
| PL45 | Growth inhibitory assay | ~5 μM | IC50=2.255 μM | 19996272 | |
| H929 | Growth inhibitory assay | ~5 μM | IC50=0.014 μM | 19996272 | |
| NCI-446 | Growth inhibitory assay | ~5 μM | IC50=1.154 μM | 19996272 | |
| Hs700t | Growth inhibitory assay | ~5 μM | IC50=0.231 μM | 19996272 | |
| U266 B1 | Growth inhibitory assay | ~5 μM | IC50=1.669 μM | 19996272 | |
| SHP-77 | Growth inhibitory assay | ~5 μM | IC50=1.888 μM | 19996272 | |
| HPAF-II | Growth inhibitory assay | ~5 μM | IC50=0.644 μM | 19996272 | |
| RPMI 8226 | Growth inhibitory assay | ~5 μM | IC50=1.293 μM | 19996272 | |
| SA-4 | Growth inhibitory assay | ~5 μM | IC50=1.301 μM | 19996272 | |
| PANC-1 BM | Growth inhibitory assay | ~5 μM | IC50>5.00 μM | 19996272 | |
| OCI-LY19 (B-cell) | Growth inhibitory assay | ~5 μM | IC50=0.4 μM | 19996272 | |
| To184.T | Growth inhibitory assay | ~5 μM | IC50=0.469 μM | 19996272 | |
| PANC-1 | Growth inhibitory assay | ~5 μM | IC50>5.00 μM | 19996272 | |
| OCI-LY10 (B-cell) | Growth inhibitory assay | ~5 μM | IC50=0.45 μM | 19996272 | |
| HTB-92 | Growth inhibitory assay | ~5 μM | IC50=1.02 μM | 19996272 | |
| Bxpc-3 | Growth inhibitory assay | ~5 μM | IC50>5.00 μM | 19996272 | |
| Bxpc-1 | Growth inhibitory assay | ~5 μM | IC50=1.924 μM | 19996272 | |
| U937 (Histioocytic) | Growth inhibitory assay | ~5 μM | IC50>5.00 μM | 19996272 | |
| SHSY5Y | Growth inhibitory assay | ~5 μM | IC50=0.106 μM | 19996272 | |
| Capan-2 | Growth inhibitory assay | ~5 μM | IC50=1.774 μM | 19996272 | |
| MEC-1 (Chronic B cell) | Growth inhibitory assay | ~5 μM | IC50=2.637 μM | 19996272 | |
| SK-NSH | Growth inhibitory assay | ~5 μM | IC50=0.139 μM | 19996272 | |
| Aspc-1 | Growth inhibitory assay | ~5 μM | IC50=0.379 μM | 19996272 | |
| Daudi (Burkitt's) | Growth inhibitory assay | ~5 μM | IC50=2.637 μM | 19996272 | |
| IMR-32 | Growth inhibitory assay | ~5 μM | IC50=0.261 μM | 19996272 | |
| HS766T | Growth inhibitory assay | ~5 μM | IC50=2.001 μM | 19996272 | |
| ST486 | Growth inhibitory assay | ~5 μM | IC50=1.19 μM | 19996272 | |
| LAN-1 | Growth inhibitory assay | ~5 μM | IC50=0.04 μM | 19996272 | |
| HTB-47 | Growth inhibitory assay | ~5 μM | IC50=2.056 μM | 19996272 | |
| CTLL2 | Growth inhibitory assay | ~5 μM | IC50>1.00 μM | 19996272 | |
| SK-NAS | Growth inhibitory assay | ~5 μM | IC50=0.497 μM | 19996272 | |
| HTB-46 | Growth inhibitory assay | ~5 μM | IC50=5.25 μM | 19996272 | |
| SET2 | Growth inhibitory assay | ~5 μM | IC50=0.298 μM | 19996272 | |
| DAOY | Growth inhibitory assay | ~5 μM | IC50=1.979 μM | 19996272 | |
| HEK293 | Growth inhibitory assay | ~5 μM | IC50=0.915 μM | 19996272 | |
| THP-1 | Growth inhibitory assay | ~5 μM | IC50=6.58 μM | 19996272 | |
| PFSK-1 | Growth inhibitory assay | ~5 μM | IC50=0.132 μM | 19996272 | |
| 151-B | Growth inhibitory assay | ~5 μM | IC50=2.67 μM | 19996272 | |
| TALL-1 (T-cell) | Growth inhibitory assay | ~5 μM | IC50=1.28 μM | 19996272 | |
| A673 | Growth inhibitory assay | ~5 μM | IC50=0.408 μM | 19996272 | |
| 786-O | Growth inhibitory assay | ~5 μM | IC50=1.647 μM | 19996272 | |
| OCI-AML 2 (acute myeloid) | Growth inhibitory assay | ~5 μM | IC50=3.33 μM | 19996272 | |
| RD1 | Growth inhibitory assay | ~5 μM | IC50=0.068 μM | 19996272 | |
| ovcar-5 | Growth inhibitory assay | ~5 μM | IC50=0.05 μM | 19996272 | |
| Mutz 2 (acute myeloid) | Growth inhibitory assay | ~5 μM | IC50=1.15 μM | 19996272 | |
| Rh41 | Growth inhibitory assay | ~5 μM | IC50=0.005 μM | 19996272 | |
| ovcar-4 | Growth inhibitory assay | ~5 μM | IC50=1 μM | 19996272 | |
| MOLM-13 (acute myeloid) | Growth inhibitory assay | ~5 μM | IC50=0.42 μM | 19996272 | |
| Rh36 | Growth inhibitory assay | ~5 μM | IC50=1.432 μM | 19996272 | |
| ovcar-3 | Growth inhibitory assay | ~5 μM | IC50=5 μM | 19996272 | |
| ML2 (Myelomonocytic) | Growth inhibitory assay | ~5 μM | IC50=0.09 μM | 19996272 | |
| CTR | Growth inhibitory assay | ~5 μM | IC50=0.253 μM | 19996272 | |
| sw-626 | Growth inhibitory assay | ~5 μM | IC50=2.306 μM | 19996272 | |
| L1210 (Murine lymphocytic) | Growth inhibitory assay | ~5 μM | IC50=2.39 μM | 19996272 | |
| ME | Growth inhibitory assay | ~5 μM | IC50=0.015 μM | 19996272 | |
| sk-ov-3 | Growth inhibitory assay | ~5 μM | IC50=5.1 μM | 19996272 | |
| Kasumi-1 (acute myeloid) | Growth inhibitory assay | ~5 μM | IC50=0.16 μM | 19996272 | |
| Rh1 | Growth inhibitory assay | ~5 μM | IC50=0.027 μM | 19996272 | |
| A2780R | Growth inhibitory assay | ~5 μM | IC50=1.564 μM | 19996272 | |
| HPN-ALL (T-cell) | Growth inhibitory assay | ~5 μM | IC50=0.52 μM | 19996272 | |
| TC71 | Growth inhibitory assay | ~5 μM | IC50=0.014 μM | 19996272 | |
| TOV 21G | Growth inhibitory assay | ~5 μM | IC50=4.279 μM | 19996272 | |
| HL60 (acute myelocytic) | Growth inhibitory assay | ~5 μM | IC50=0.12 μM | 19996272 | |
| TC32 | Growth inhibitory assay | ~5 μM | IC50=0.008 μM | 19996272 | |
| TOV 112D | Growth inhibitory assay | ~5 μM | IC50=2.146 μM | 19996272 | |
| B6-T315I (Murine B-ALL) | Growth inhibitory assay | ~5 μM | IC50=2.83 μM | 19996272 | |
| RDES | Growth inhibitory assay | ~5 μM | IC50=0.012 μM | 19996272 | |
| A2780/S | Growth inhibitory assay | ~5 μM | IC50=0.122 μM | 19996272 | |
| P388 (Murine) | Growth inhibitory assay | ~5 μM | IC50=4.27 μM | 19996272 | |
| 5838 | Growth inhibitory assay | ~5 μM | IC50=0.034 μM | 19996272 | |
| 22-r-1 | Growth inhibitory assay | ~5 μM | IC50=0.175 μM | 19996272 | |
| RS411 (B cell precursor-ALL) | Growth inhibitory assay | ~5 μM | IC50=0.102 μM | 19996272 | |
| LG | Growth inhibitory assay | ~5 μM | IC50=0.038 μM | 19996272 | |
| MDA-PCa-2b | Growth inhibitory assay | ~5 μM | IC50=0.098 μM | 19996272 | |
| MV411 (B Myelomonocytic) | Growth inhibitory assay | ~5 μM | IC50=0.33 μM | 19996272 | |
| VW | Growth inhibitory assay | ~5 μM | IC50=0.019 μM | 19996272 | |
| LN CAP-FGC | Growth inhibitory assay | ~5 μM | IC50=1.434 μM | 19996272 | |
| B6-P210 (Murine ALL) | Growth inhibitory assay | ~5 μM | IC50=1.293 μM | 19996272 | |
| K-562 (CML) | Growth inhibitory assay | ~5 μM | IC50=2.302 μM | 19996272 | |
| KAG | Growth inhibitory assay | ~5 μM | IC50=1.665 μM | 19996272 | |
| DU145 | Growth inhibitory assay | ~5 μM | IC50=1.465 μM | 19996272 | |
| JD | Growth inhibitory assay | ~5 μM | IC50=0.391 μM | 19996272 | |
| PC3 | Growth inhibitory assay | ~5 μM | IC50=0.965 μM | 19996272 | |
| CCRF-CEM (ALL) | Growth inhibitory assay | ~5 μM | IC50=1.239 μM | 19996272 | |
| BT549 | Growth inhibitory assay | ~5 μM | IC50=1.645 μM | 19996272 | |
| HCT116/VM46 | Growth inhibitory assay | ~5 μM | IC50=1.702 μM | 19996272 | |
| H460 | Growth inhibitory assay | ~5 μM | IC50=0.795 μM | 19996272 | |
| MCF-7 | Growth inhibitory assay | ~5 μM | IC50=0.016 μM | 19996272 | |
| GEO | Growth inhibitory assay | ~5 μM | IC50=0.356 μM | 19996272 | |
| H441 0.646 | Growth inhibitory assay | ~5 μM | IC50=0.646 μM | 19996272 | |
| MCF-7-807R | Growth inhibitory assay | ~5 μM | IC50=0.49 μM | 19996272 | |
| Colo205 | Growth inhibitory assay | ~5 μM | IC50=0.104 μM | 19996272 | |
| H292 | Growth inhibitory assay | ~5 μM | IC50=0.788 μM | 19996272 | |
| BT474 (S) | Growth inhibitory assay | ~5 μM | IC50=2.403 μM | 19996272 | |
| HT-29 | Growth inhibitory assay | ~5 μM | IC50=2.103 μM | 19996272 | |
| A549 | Growth inhibitory assay | ~5 μM | IC50=0.675 μM | 19996272 | |
| BT474-M1 | Growth inhibitory assay | ~5 μM | IC50=2.365 μM | 19996272 | |
| SW480 | Growth inhibitory assay | ~5 μM | IC50>5.00 μM | 19996272 | |
| L2987 | Growth inhibitory assay | ~5 μM | IC50=0.442 μM | 19996272 | |
| AU565 | Growth inhibitory assay | ~5 μM | IC50=4.97 μM | 19996272 | |
| SW403 | Growth inhibitory assay | ~5 μM | IC50=0.22 μM | 19996272 | |
| H1437 | Growth inhibitory assay | ~5 μM | IC50=0.523 μM | 19996272 | |
| BT-20 | Growth inhibitory assay | ~5 μM | IC50=3.562 μM | 19996272 | |
| Colo320HSR | Growth inhibitory assay | ~5 μM | IC50=0.011 μM | 19996272 | |
| H2087 | Growth inhibitory assay | ~5 μM | IC50>1.00 μM | 19996272 | |
| HCC1419 | Growth inhibitory assay | ~5 μM | IC50=2.517 μM | 19996272 | |
| WiDr | Growth inhibitory assay | ~5 μM | IC50=0.076 μM | 19996272 | |
| H661 0.573 | Growth inhibitory assay | ~5 μM | IC50=0.573 μM | 19996272 | |
| HCC-38 | Growth inhibitory assay | ~5 μM | IC50>5.00 μM | 19996272 | |
| LS174T | Growth inhibitory assay | ~5 μM | IC50=0.535 μM | 19996272 | |
| H211 | Growth inhibitory assay | ~5 μM | IC50=0.733 μM | 19996272 | |
| HCC70 | Growth inhibitory assay | ~5 μM | IC50=1.55 μM | 19996272 | |
| SW116 | Growth inhibitory assay | ~5 μM | IC50=0.067 μM | 19996272 | |
| H513 | Growth inhibitory assay | ~5 μM | IC50=4.448 μM | 19996272 | |
| MDA-MB-157 | Growth inhibitory assay | ~5 μM | IC50=0.036 μM | 19996272 | |
| H2052 | Growth inhibitory assay | ~5 μM | IC50=1.05 μM | 19996272 | |
| MDA-MB-415 | Growth inhibitory assay | ~5 μM | IC50>5.00 μM | 19996272 | |
| DLD-1 | Growth inhibitory assay | ~5 μM | IC50=0.909 μM | 19996272 | |
| H2595 | Growth inhibitory assay | ~5 μM | IC50=4.475 μM | 19996272 | |
| MDA-MB-435S | Growth inhibitory assay | ~5 μM | IC50=1.869 μM | 19996272 | |
| HCT15 | Growth inhibitory assay | ~5 μM | IC50>1.00 μM | 19996272 | |
| SK-Hep1 | Growth inhibitory assay | ~5 μM | IC50=0.146 μM | 19996272 | |
| MDA-MB-436 | Growth inhibitory assay | ~5 μM | IC50=5.502 μM | 19996272 | |
| KM12C | Growth inhibitory assay | ~5 μM | IC50=0.054 μM | 19996272 | |
| HEPG2 | Growth inhibitory assay | ~5 μM | IC50=0.025 μM | 19996272 | |
| MDA-MB-453 | Growth inhibitory assay | ~5 μM | IC50=1.869 μM | 19996272 | |
| KM12SM | Growth inhibitory assay | ~5 μM | IC50=0.059 μM | 19996272 | |
| 1483 | Growth inhibitory assay | ~5 μM | IC50=2.19 μM | 19996272 | |
| Hs578t | Growth inhibitory assay | ~5 μM | IC50=1.287 μM | 19996272 | |
| LS180 | Growth inhibitory assay | ~5 μM | IC50=0.696 μM | 19996272 | |
| FaDu | Growth inhibitory assay | ~5 μM | IC50=1.27 μM | 19996272 | |
| ZR-75-1 | Growth inhibitory assay | ~5 μM | IC50=2.084 μM | 19996272 | |
| LS513 | Growth inhibitory assay | ~5 μM | IC50=0.135 μM | 19996272 | |
| Detroit.562 | Growth inhibitory assay | ~5 μM | IC50=1.14 μM | 19996272 | |
| ZR-75-30 | Growth inhibitory assay | ~5 μM | IC50>5.00 μM | 19996272 | |
| RKO-PM | Growth inhibitory assay | ~5 μM | IC50=0.232 μM | 19996272 | |
| Cal.27 | Growth inhibitory assay | ~5 μM | IC50=2 μM | 19996272 | |
| KPL4 | Growth inhibitory assay | ~5 μM | IC50=1.252 μM | 19996272 | |
| PKO-RM13 | Growth inhibitory assay | ~5 μM | IC50=0.425 μM | 19996272 | |
| HS.53.T | Growth inhibitory assay | ~5 μM | IC50=0.79 μM | 19996272 | |
| EMT6 | Growth inhibitory assay | ~5 μM | IC50=0.806 μM | 19996272 | |
| SNU-C1 | Growth inhibitory assay | ~5 μM | IC50=0.007 μM | 19996272 | |
| SQCCY1 | Growth inhibitory assay | ~5 μM | IC50=0.79 μM | 19996272 | |
| SW480 | Growth inhibitory assay | ~5 μM | IC50=0.037 μM | 19996272 | |
| SCC9 | Growth inhibitory assay | ~5 μM | IC50=0.75 μM | 19996272 | |
| SK-LMS-1 | Growth inhibitory assay | ~5 μM | IC50=0.687 μM | 19996272 | |
| SCC25 | Growth inhibitory assay | ~5 μM | IC50=0.68 μM | 19996272 | |
| U87 | Growth inhibitory assay | ~5 μM | IC50=0.95 μM | 19996272 | |
| SCC15 | Growth inhibitory assay | ~5 μM | IC50=0.67 μM | 19996272 | |
| T98G | Growth inhibitory assay | ~5 μM | IC50=1.218 μM | 19996272 | |
| SCC4 | Growth inhibitory assay | ~5 μM | IC50=0.63 μM | 19996272 | |
| U118 | Growth inhibitory assay | ~5 μM | IC50=1.618 μM | 19996272 | |
| TU167 | Growth inhibitory assay | ~5 μM | IC50=4.52 μM | 19996272 | |
| NCI-H727 | Growth inhibitory assay | ~10 μM | IC50=428 nM | 20385747 | |
| NCI-H720 | Growth inhibitory assay | ~10 μM | IC50=2.8 μM | 20385747 | |
| NCI-H835 | Growth inhibitory assay | ~10 μM | IC50=1 μM | 20385747 | |
| NCI-H727 | Kinase assay | ~10 μM | inhibits constitutive IGF1R autophosphorylation | 20385747 | |
| RD | Growth inhibitory assay | ~10 μM | IC50=1.12 µM | 21298745 | |
| Rh41 | Growth inhibitory assay | ~10 μM | IC50=0.07 µM | 21298745 | |
| Rh18 | Growth inhibitory assay | ~10 μM | IC50=4.96 µM | 21298745 | |
| Rh30 | Growth inhibitory assay | ~10 μM | IC50=0.19 µM | 21298745 | |
| BT-12 | Growth inhibitory assay | ~10 μM | IC50=0.78 µM | 21298745 | |
| CHLA-266 | Growth inhibitory assay | ~10 μM | IC50=0.89 µM | 21298745 | |
| TC-71 | Growth inhibitory assay | ~10 μM | IC50=0.11 µM | 21298745 | |
| CHLA-9 | Growth inhibitory assay | ~10 μM | IC50=0.12 µM | 21298745 | |
| CHLA-10 | Growth inhibitory assay | ~10 μM | IC50=0.62 µM | 21298745 | |
| CHLA-258 | Growth inhibitory assay | ~10 μM | IC50=0.27 µM | 21298745 | |
| GBM2 | Growth inhibitory assay | ~10 μM | IC50=1.47 µM | 21298745 | |
| NB-1643 | Growth inhibitory assay | ~10 μM | IC50=0.12 µM | 21298745 | |
| NB-EBc1 | Growth inhibitory assay | ~10 μM | IC50=0.35 µM | 21298745 | |
| CHLA-90 | Growth inhibitory assay | ~10 μM | IC50=0.77 µM | 21298745 | |
| CHLA-136 | Growth inhibitory assay | ~10 μM | IC50=0.52 µM | 21298745 | |
| NALM-6 | Growth inhibitory assay | ~10 μM | IC50=0.49 µM | 21298745 | |
| COG-LL-317 | Growth inhibitory assay | ~10 μM | IC50=1.38 µM | 21298745 | |
| RS4;11 | Growth inhibitory assay | ~10 μM | IC50=0.38 µM | 21298745 | |
| MOLT-4 | Growth inhibitory assay | ~10 μM | IC50=0.53 µM | 21298745 | |
| CCRF-CEM | Growth inhibitory assay | ~10 μM | IC50=1.13 µM | 21298745 | |
| Kasumi-1 | Growth inhibitory assay | ~10 μM | IC50=1.2 µM | 21298745 | |
| Karpas-299 | Growth inhibitory assay | ~10 μM | IC50=1.64 µM | 21298745 | |
| Ramos-RA1 | Growth inhibitory assay | ~10 μM | IC50=1.31 µM | 21298745 | |
| A549 | Kinase assay | 0.5 μM | inhibits IGF-IR/IR activation | 26928578 | |
| NCI-H358 | Kinase assay | 0.5 μM | inhibits IGF-IR/IR activation | 26928578 | |
| A549 | Function assay | 0.5 μM | causes a concurrent decrease in phosphorylated AKT and ERK | 26928578 | |
| NCI-H358 | Function assay | 0.5 μM | causes a concurrent decrease in phosphorylated AKT and ERK | 26928578 | |
| A549 | Growth inhibitory assay | ~10 μM | IC50=0.76 μM | 26928578 | |
| NCI-H358 | Growth inhibitory assay | ~10 μM | IC50=1.09 μM | 26928578 | |
| A549 | Apoptosis assay | 0.5 μM | induces Apoptosis | 26928578 | |
| NCI-H358 | Apoptosis assay | 0.5 μM | induces Apoptosis | 26928578 | |
| A549 | Function assay | 0.5 μM | reduces wound closure | 26928578 | |
| NCI-H358 | Function assay | 0.5 μM | reduces wound closure | 26928578 | |
| IGF-Sal | Growth inhibitory assay | IC50=7 nM | 19778024 | ||
| IGF-Sal | Kinase assay | inhibits the phosphorylation of IGF-1R (IC50 = 13nM) and the downstream targets Akt (IC50 = 22nM) and MAPK (IC50 = 13nM) | 19778024 | ||
| Rh30 | Function assay | induces an increase of SFK phosphorylation | 25925378 | ||
| Rh41 | Function assay | induces an increase of SFK phosphorylation | 25925378 | ||
| RD | Function assay | induces an increase of SFK phosphorylation | 25925378 | ||
| IGF1R-SAL | Function assay | Inhibition of IGF1R in IGF1R-SAL cells, IC50 = 0.0021 μM. | 20675137 | ||
| TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 29435139 | ||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 29435139 | ||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | ||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | ||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | ||
| Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 29435139 | ||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 29435139 | ||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 29435139 | ||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 29435139 | ||
| Rh18 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 29435139 | ||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | ||
| MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 29435139 | ||
| wild type fibroblast cells | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 29435139 | ||
| Rh41 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 29435139 | ||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells | 29435139 | ||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) | 29435139 | ||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells | 29435139 | ||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells | 29435139 | ||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells | 29435139 | ||
| TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells | 29435139 | ||
| MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells | 29435139 | ||
| wild type fibroblast cells | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells | 29435139 | ||
| U-2 OS | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells | 29435139 | ||
| Rh41 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells | 29435139 | ||
| Rh18 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells | 29435139 | ||
| Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells | 29435139 | ||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells | 29435139 | ||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells | 29435139 | ||
| COLO-205 | Growth Inhibition Assay | Inhibition of human COLO-205 cell growth in a cell viability assay, IC50 = 0.002243 μM. | SANGER | ||
| EW-1 | Growth Inhibition Assay | Inhibition of human EW-1 cell growth in a cell viability assay, IC50 = 0.003998 μM. | SANGER | ||
| TE-11 | Growth Inhibition Assay | Inhibition of human TE-11 cell growth in a cell viability assay, IC50 = 0.004197 μM. | SANGER | ||
| A4-Fuk | Growth Inhibition Assay | Inhibition of human A4-Fuk cell growth in a cell viability assay, IC50 = 0.0057 μM. | SANGER | ||
| PANC-08-13 | Growth Inhibition Assay | Inhibition of human PANC-08-13 cell growth in a cell viability assay, IC50 = 0.008604 μM. | SANGER | ||
| Saos-2 | Growth Inhibition Assay | Inhibition of human Saos-2 cell growth in a cell viability assay, IC50 = 0.00962 μM. | SANGER | ||
| HT-29 | Growth Inhibition Assay | Inhibition of human HT-29 cell growth in a cell viability assay, IC50 = 0.01226 μM. | SANGER | ||
| NCI-H1355 | Growth Inhibition Assay | Inhibition of human NCI-H1355 cell growth in a cell viability assay, IC50 = 0.01401 μM. | SANGER | ||
| NCI-H2122 | Growth Inhibition Assay | Inhibition of human NCI-H2122 cell growth in a cell viability assay, IC50 = 0.01458 μM. | SANGER | ||
| ES1 | Growth Inhibition Assay | Inhibition of human ES1 cell growth in a cell viability assay, IC50 = 0.01594 μM. | SANGER | ||
| KS-1 | Growth Inhibition Assay | Inhibition of human KS-1 cell growth in a cell viability assay, IC50 = 0.01594 μM. | SANGER | ||
| EW-16 | Growth Inhibition Assay | Inhibition of human EW-16 cell growth in a cell viability assay, IC50 = 0.02095 μM. | SANGER | ||
| LB771-HNC | Growth Inhibition Assay | Inhibition of human LB771-HNC cell growth in a cell viability assay, IC50 = 0.02296 μM. | SANGER | ||
| NCI-H650 | Growth Inhibition Assay | Inhibition of human NCI-H650 cell growth in a cell viability assay, IC50 = 0.02652 μM. | SANGER | ||
| NCI-H727 | Growth Inhibition Assay | Inhibition of human NCI-H727 cell growth in a cell viability assay, IC50 = 0.03011 μM. | SANGER | ||
| NOS-1 | Growth Inhibition Assay | Inhibition of human NOS-1 cell growth in a cell viability assay, IC50 = 0.03084 μM. | SANGER | ||
| T84 | Growth Inhibition Assay | Inhibition of human T84 cell growth in a cell viability assay, IC50 = 0.03359 μM. | SANGER | ||
| SNU-387 | Growth Inhibition Assay | Inhibition of human SNU-387 cell growth in a cell viability assay, IC50 = 0.03578 μM. | SANGER | ||
| TE-8 | Growth Inhibition Assay | Inhibition of human TE-8 cell growth in a cell viability assay, IC50 = 0.03654 μM. | SANGER | ||
| ML-2 | Growth Inhibition Assay | Inhibition of human ML-2 cell growth in a cell viability assay, IC50 = 0.03695 μM. | SANGER | ||
| HT-144 | Growth Inhibition Assay | Inhibition of human HT-144 cell growth in a cell viability assay, IC50 = 0.03791 μM. | SANGER | ||
| LCLC-97TM1 | Growth Inhibition Assay | Inhibition of human LCLC-97TM1 cell growth in a cell viability assay, IC50 = 0.04354 μM. | SANGER | ||
| LS-1034 | Growth Inhibition Assay | Inhibition of human LS-1034 cell growth in a cell viability assay, IC50 = 0.04606 μM. | SANGER | ||
| BFTC-905 | Growth Inhibition Assay | Inhibition of human BFTC-905 cell growth in a cell viability assay, IC50 = 0.04727 μM. | SANGER | ||
| SIG-M5 | Growth Inhibition Assay | Inhibition of human SIG-M5 cell growth in a cell viability assay, IC50 = 0.04819 μM. | SANGER | ||
| GDM-1 | Growth Inhibition Assay | Inhibition of human GDM-1 cell growth in a cell viability assay, IC50 = 0.05338 μM. | SANGER | ||
| GP5d | Growth Inhibition Assay | Inhibition of human GP5d cell growth in a cell viability assay, IC50 = 0.05404 μM. | SANGER | ||
| NCI-H358 | Growth Inhibition Assay | Inhibition of human NCI-H358 cell growth in a cell viability assay, IC50 = 0.05571 μM. | SANGER | ||
| EW-11 | Growth Inhibition Assay | Inhibition of human EW-11 cell growth in a cell viability assay, IC50 = 0.0558 μM. | SANGER | ||
| KM12 | Growth Inhibition Assay | Inhibition of human KM12 cell growth in a cell viability assay, IC50 = 0.05722 μM. | SANGER | ||
| EW-7 | Growth Inhibition Assay | Inhibition of human EW-7 cell growth in a cell viability assay, IC50 = 0.06101 μM. | SANGER | ||
| A375 | Growth Inhibition Assay | Inhibition of human A375 cell growth in a cell viability assay, IC50 = 0.06678 μM. | SANGER | ||
| G-401 | Growth Inhibition Assay | Inhibition of human G-401 cell growth in a cell viability assay, IC50 = 0.06781 μM. | SANGER | ||
| IGROV-1 | Growth Inhibition Assay | Inhibition of human IGROV-1 cell growth in a cell viability assay, IC50 = 0.06857 μM. | SANGER | ||
| MFH-ino | Growth Inhibition Assay | Inhibition of human MFH-ino cell growth in a cell viability assay, IC50 = 0.07149 μM. | SANGER | ||
| MEL-JUSO | Growth Inhibition Assay | Inhibition of human MEL-JUSO cell growth in a cell viability assay, IC50 = 0.07154 μM. | SANGER | ||
| EW-18 | Growth Inhibition Assay | Inhibition of human EW-18 cell growth in a cell viability assay, IC50 = 0.07157 μM. | SANGER | ||
| HCC2998 | Growth Inhibition Assay | Inhibition of human HCC2998 cell growth in a cell viability assay, IC50 = 0.0719 μM. | SANGER | ||
| ES4 | Growth Inhibition Assay | Inhibition of human ES4 cell growth in a cell viability assay, IC50 = 0.07293 μM. | SANGER | ||
| SK-N-DZ | Growth Inhibition Assay | Inhibition of human SK-N-DZ cell growth in a cell viability assay, IC50 = 0.07792 μM. | SANGER | ||
| PSN1 | Growth Inhibition Assay | Inhibition of human PSN1 cell growth in a cell viability assay, IC50 = 0.07822 μM. | SANGER | ||
| CAL-39 | Growth Inhibition Assay | Inhibition of human CAL-39 cell growth in a cell viability assay, IC50 = 0.08259 μM. | SANGER | ||
| SNU-C1 | Growth Inhibition Assay | Inhibition of human SNU-C1 cell growth in a cell viability assay, IC50 = 0.08617 μM. | SANGER | ||
| CMK | Growth Inhibition Assay | Inhibition of human CMK cell growth in a cell viability assay, IC50 = 0.09283 μM. | SANGER | ||
| MCF7 | Growth Inhibition Assay | Inhibition of human MCF7 cell growth in a cell viability assay, IC50 = 0.09299 μM. | SANGER | ||
| ES8 | Growth Inhibition Assay | Inhibition of human ES8 cell growth in a cell viability assay, IC50 = 0.10016 μM. | SANGER | ||
| RS4-11 | Growth Inhibition Assay | Inhibition of human RS4-11 cell growth in a cell viability assay, IC50 = 0.1024 μM. | SANGER | ||
| NCI-H1437 | Growth Inhibition Assay | Inhibition of human NCI-H1437 cell growth in a cell viability assay, IC50 = 0.10534 μM. | SANGER | ||
| SJRH30 | Growth Inhibition Assay | Inhibition of human SJRH30 cell growth in a cell viability assay, IC50 = 0.10982 μM. | SANGER | ||
| GCIY | Growth Inhibition Assay | Inhibition of human GCIY cell growth in a cell viability assay, IC50 = 0.11182 μM. | SANGER | ||
| ABC-1 | Growth Inhibition Assay | Inhibition of human ABC-1 cell growth in a cell viability assay, IC50 = 0.11695 μM. | SANGER | ||
| MHH-ES-1 | Growth Inhibition Assay | Inhibition of human MHH-ES-1 cell growth in a cell viability assay, IC50 = 0.12206 μM. | SANGER | ||
| NCI-H2228 | Growth Inhibition Assay | Inhibition of human NCI-H2228 cell growth in a cell viability assay, IC50 = 0.12427 μM. | SANGER | ||
| COR-L105 | Growth Inhibition Assay | Inhibition of human COR-L105 cell growth in a cell viability assay, IC50 = 0.13232 μM. | SANGER | ||
| NCI-H810 | Growth Inhibition Assay | Inhibition of human NCI-H810 cell growth in a cell viability assay, IC50 = 0.13707 μM. | SANGER | ||
| CHP-212 | Growth Inhibition Assay | Inhibition of human CHP-212 cell growth in a cell viability assay, IC50 = 0.15162 μM. | SANGER | ||
| LB647-SCLC | Growth Inhibition Assay | Inhibition of human LB647-SCLC cell growth in a cell viability assay, IC50 = 0.1549 μM. | SANGER | ||
| NCI-H1648 | Growth Inhibition Assay | Inhibition of human NCI-H1648 cell growth in a cell viability assay, IC50 = 0.16075 μM. | SANGER | ||
| RH-1 | Growth Inhibition Assay | Inhibition of human RH-1 cell growth in a cell viability assay, IC50 = 0.16629 μM. | SANGER | ||
| CAL-85-1 | Growth Inhibition Assay | Inhibition of human CAL-85-1 cell growth in a cell viability assay, IC50 = 0.16738 μM. | SANGER | ||
| NB10 | Growth Inhibition Assay | Inhibition of human NB10 cell growth in a cell viability assay, IC50 = 0.17084 μM. | SANGER | ||
| RPMI-2650 | Growth Inhibition Assay | Inhibition of human RPMI-2650 cell growth in a cell viability assay, IC50 = 0.17567 μM. | SANGER | ||
| NTERA-S-cl-D1 | Growth Inhibition Assay | Inhibition of human NTERA-S-cl-D1 cell growth in a cell viability assay, IC50 = 0.17778 μM. | SANGER | ||
| NH-12 | Growth Inhibition Assay | Inhibition of human NH-12 cell growth in a cell viability assay, IC50 = 0.17943 μM. | SANGER | ||
| COLO-320-HSR | Growth Inhibition Assay | Inhibition of human COLO-320-HSR cell growth in a cell viability assay, IC50 = 0.17958 μM. | SANGER | ||
| MC-IXC | Growth Inhibition Assay | Inhibition of human MC-IXC cell growth in a cell viability assay, IC50 = 0.17996 μM. | SANGER | ||
| HMV-II | Growth Inhibition Assay | Inhibition of human HMV-II cell growth in a cell viability assay, IC50 = 0.18325 μM. | SANGER | ||
| LS-411N | Growth Inhibition Assay | Inhibition of human LS-411N cell growth in a cell viability assay, IC50 = 0.18349 μM. | SANGER | ||
| RD | Growth Inhibition Assay | Inhibition of human RD cell growth in a cell viability assay, IC50 = 0.18531 μM. | SANGER | ||
| DOK | Growth Inhibition Assay | Inhibition of human DOK cell growth in a cell viability assay, IC50 = 0.19484 μM. | SANGER | ||
| SK-CO-1 | Growth Inhibition Assay | Inhibition of human SK-CO-1 cell growth in a cell viability assay, IC50 = 0.19724 μM. | SANGER | ||
| LAN-6 | Growth Inhibition Assay | Inhibition of human LAN-6 cell growth in a cell viability assay, IC50 = 0.19876 μM. | SANGER | ||
| NCI-H747 | Growth Inhibition Assay | Inhibition of human NCI-H747 cell growth in a cell viability assay, IC50 = 0.19905 μM. | SANGER | ||
| Capan-2 | Growth Inhibition Assay | Inhibition of human Capan-2 cell growth in a cell viability assay, IC50 = 0.20635 μM. | SANGER | ||
| NMC-G1 | Growth Inhibition Assay | Inhibition of human NMC-G1 cell growth in a cell viability assay, IC50 = 0.20852 μM. | SANGER | ||
| ES6 | Growth Inhibition Assay | Inhibition of human ES6 cell growth in a cell viability assay, IC50 = 0.21402 μM. | SANGER | ||
| MZ1-PC | Growth Inhibition Assay | Inhibition of human MZ1-PC cell growth in a cell viability assay, IC50 = 0.21584 μM. | SANGER | ||
| SW1710 | Growth Inhibition Assay | Inhibition of human SW1710 cell growth in a cell viability assay, IC50 = 0.216 μM. | SANGER | ||
| PANC-10-05 | Growth Inhibition Assay | Inhibition of human PANC-10-05 cell growth in a cell viability assay, IC50 = 0.21713 μM. | SANGER | ||
| ES3 | Growth Inhibition Assay | Inhibition of human ES3 cell growth in a cell viability assay, IC50 = 0.22285 μM. | SANGER | ||
| SK-PN-DW | Growth Inhibition Assay | Inhibition of human SK-PN-DW cell growth in a cell viability assay, IC50 = 0.22786 μM. | SANGER | ||
| SK-NEP-1 | Growth Inhibition Assay | Inhibition of human SK-NEP-1 cell growth in a cell viability assay, IC50 = 0.22835 μM. | SANGER | ||
| A427 | Growth Inhibition Assay | Inhibition of human A427 cell growth in a cell viability assay, IC50 = 0.24322 μM. | SANGER | ||
| SK-LU-1 | Growth Inhibition Assay | Inhibition of human SK-LU-1 cell growth in a cell viability assay, IC50 = 0.2433 μM. | SANGER | ||
| MIA-PaCa-2 | Growth Inhibition Assay | Inhibition of human MIA-PaCa-2 cell growth in a cell viability assay, IC50 = 0.25262 μM. | SANGER | ||
| SK-MEL-3 | Growth Inhibition Assay | Inhibition of human SK-MEL-3 cell growth in a cell viability assay, IC50 = 0.25834 μM. | SANGER | ||
| LC-2-ad | Growth Inhibition Assay | Inhibition of human LC-2-ad cell growth in a cell viability assay, IC50 = 0.27037 μM. | SANGER | ||
| MG-63 | Growth Inhibition Assay | Inhibition of human MG-63 cell growth in a cell viability assay, IC50 = 0.27622 μM. | SANGER | ||
| HUTU-80 | Growth Inhibition Assay | Inhibition of human HUTU-80 cell growth in a cell viability assay, IC50 = 0.27884 μM. | SANGER | ||
| HCC70 | Growth Inhibition Assay | Inhibition of human HCC70 cell growth in a cell viability assay, IC50 = 0.28448 μM. | SANGER | ||
| SJSA-1 | Growth Inhibition Assay | Inhibition of human SJSA-1 cell growth in a cell viability assay, IC50 = 0.3261 μM. | SANGER | ||
| SIMA | Growth Inhibition Assay | Inhibition of human SIMA cell growth in a cell viability assay, IC50 = 0.34069 μM. | SANGER | ||
| LK-2 | Growth Inhibition Assay | Inhibition of human LK-2 cell growth in a cell viability assay, IC50 = 0.34124 μM. | SANGER | ||
| EKVX | Growth Inhibition Assay | Inhibition of human EKVX cell growth in a cell viability assay, IC50 = 0.35075 μM. | SANGER | ||
| NCI-H441 | Growth Inhibition Assay | Inhibition of human NCI-H441 cell growth in a cell viability assay, IC50 = 0.35395 μM. | SANGER | ||
| A431 | Growth Inhibition Assay | Inhibition of human A431 cell growth in a cell viability assay, IC50 = 0.35421 μM. | SANGER | ||
| HCC2157 | Growth Inhibition Assay | Inhibition of human HCC2157 cell growth in a cell viability assay, IC50 = 0.35686 μM. | SANGER | ||
| TGBC24TKB | Growth Inhibition Assay | Inhibition of human TGBC24TKB cell growth in a cell viability assay, IC50 = 0.35705 μM. | SANGER | ||
| TE-12 | Growth Inhibition Assay | Inhibition of human TE-12 cell growth in a cell viability assay, IC50 = 0.35841 μM. | SANGER | ||
| GB-1 | Growth Inhibition Assay | Inhibition of human GB-1 cell growth in a cell viability assay, IC50 = 0.3628 μM. | SANGER | ||
| NB69 | Growth Inhibition Assay | Inhibition of human NB69 cell growth in a cell viability assay, IC50 = 0.36369 μM. | SANGER | ||
| NCI-H292 | Growth Inhibition Assay | Inhibition of human NCI-H292 cell growth in a cell viability assay, IC50 = 0.36962 μM. | SANGER | ||
| CAL-12T | Growth Inhibition Assay | Inhibition of human CAL-12T cell growth in a cell viability assay, IC50 = 0.37216 μM. | SANGER | ||
| GI-ME-N | Growth Inhibition Assay | Inhibition of human GI-ME-N cell growth in a cell viability assay, IC50 = 0.37933 μM. | SANGER | ||
| L-363 | Growth Inhibition Assay | Inhibition of human L-363 cell growth in a cell viability assay, IC50 = 0.38703 μM. | SANGER | ||
| SK-MM-2 | Growth Inhibition Assay | Inhibition of human SK-MM-2 cell growth in a cell viability assay, IC50 = 0.39516 μM. | SANGER | ||
| CAL-51 | Growth Inhibition Assay | Inhibition of human CAL-51 cell growth in a cell viability assay, IC50 = 0.40269 μM. | SANGER | ||
| NCI-H2171 | Growth Inhibition Assay | Inhibition of human NCI-H2171 cell growth in a cell viability assay, IC50 = 0.41171 μM. | SANGER | ||
| SK-MEL-2 | Growth Inhibition Assay | Inhibition of human SK-MEL-2 cell growth in a cell viability assay, IC50 = 0.41805 μM. | SANGER | ||
| COLO-668 | Growth Inhibition Assay | Inhibition of human COLO-668 cell growth in a cell viability assay, IC50 = 0.42737 μM. | SANGER | ||
| TCCSUP | Growth Inhibition Assay | Inhibition of human TCCSUP cell growth in a cell viability assay, IC50 = 0.43088 μM. | SANGER | ||
| CHP-126 | Growth Inhibition Assay | Inhibition of human CHP-126 cell growth in a cell viability assay, IC50 = 0.43102 μM. | SANGER | ||
| LU-99A | Growth Inhibition Assay | Inhibition of human LU-99A cell growth in a cell viability assay, IC50 = 0.44655 μM. | SANGER | ||
| SBC-5 | Growth Inhibition Assay | Inhibition of human SBC-5 cell growth in a cell viability assay, IC50 = 0.47041 μM. | SANGER | ||
| BB49-HNC | Growth Inhibition Assay | Inhibition of human BB49-HNC cell growth in a cell viability assay, IC50 = 0.47733 μM. | SANGER | ||
| SW982 | Growth Inhibition Assay | Inhibition of human SW982 cell growth in a cell viability assay, IC50 = 0.47869 μM. | SANGER | ||
| OVCAR-5 | Growth Inhibition Assay | Inhibition of human OVCAR-5 cell growth in a cell viability assay, IC50 = 0.50207 μM. | SANGER | ||
| CCF-STTG1 | Growth Inhibition Assay | Inhibition of human CCF-STTG1 cell growth in a cell viability assay, IC50 = 0.51374 μM. | SANGER | ||
| KYSE-510 | Growth Inhibition Assay | Inhibition of human KYSE-510 cell growth in a cell viability assay, IC50 = 0.51755 μM. | SANGER | ||
| TE-1 | Growth Inhibition Assay | Inhibition of human TE-1 cell growth in a cell viability assay, IC50 = 0.54963 μM. | SANGER | ||
| CPC-N | Growth Inhibition Assay | Inhibition of human CPC-N cell growth in a cell viability assay, IC50 = 0.55598 μM. | SANGER | ||
| KGN | Growth Inhibition Assay | Inhibition of human KGN cell growth in a cell viability assay, IC50 = 0.55892 μM. | SANGER | ||
| LB996-RCC | Growth Inhibition Assay | Inhibition of human LB996-RCC cell growth in a cell viability assay, IC50 = 0.56224 μM. | SANGER | ||
| TE-441-T | Growth Inhibition Assay | Inhibition of human TE-441-T cell growth in a cell viability assay, IC50 = 0.56355 μM. | SANGER | ||
| BC-1 | Growth Inhibition Assay | Inhibition of human BC-1 cell growth in a cell viability assay, IC50 = 0.58745 μM. | SANGER | ||
| 5637 | Growth Inhibition Assay | Inhibition of human 5637 cell growth in a cell viability assay, IC50 = 0.60092 μM. | SANGER | ||
| A673 | Growth Inhibition Assay | Inhibition of human A673 cell growth in a cell viability assay, IC50 = 0.60486 μM. | SANGER | ||
| OPM-2 | Growth Inhibition Assay | Inhibition of human OPM-2 cell growth in a cell viability assay, IC50 = 0.61161 μM. | SANGER | ||
| DK-MG | Growth Inhibition Assay | Inhibition of human DK-MG cell growth in a cell viability assay, IC50 = 0.61751 μM. | SANGER | ||
| HGC-27 | Growth Inhibition Assay | Inhibition of human HGC-27 cell growth in a cell viability assay, IC50 = 0.62379 μM. | SANGER | ||
| TE-10 | Growth Inhibition Assay | Inhibition of human TE-10 cell growth in a cell viability assay, IC50 = 0.63065 μM. | SANGER | ||
| VA-ES-BJ | Growth Inhibition Assay | Inhibition of human VA-ES-BJ cell growth in a cell viability assay, IC50 = 0.63247 μM. | SANGER | ||
| KOSC-2 | Growth Inhibition Assay | Inhibition of human KOSC-2 cell growth in a cell viability assay, IC50 = 0.63721 μM. | SANGER | ||
| LB1047-RCC | Growth Inhibition Assay | Inhibition of human LB1047-RCC cell growth in a cell viability assay, IC50 = 0.64357 μM. | SANGER | ||
| NCI-H1299 | Growth Inhibition Assay | Inhibition of human NCI-H1299 cell growth in a cell viability assay, IC50 = 0.64814 μM. | SANGER | ||
| AN3-CA | Growth Inhibition Assay | Inhibition of human AN3-CA cell growth in a cell viability assay, IC50 = 0.65646 μM. | SANGER | ||
| MKN45 | Growth Inhibition Assay | Inhibition of human MKN45 cell growth in a cell viability assay, IC50 = 0.65987 μM. | SANGER | ||
| BB30-HNC | Growth Inhibition Assay | Inhibition of human BB30-HNC cell growth in a cell viability assay, IC50 = 0.66381 μM. | SANGER | ||
| HSC-3 | Growth Inhibition Assay | Inhibition of human HSC-3 cell growth in a cell viability assay, IC50 = 0.66843 μM. | SANGER | ||
| SNB75 | Growth Inhibition Assay | Inhibition of human SNB75 cell growth in a cell viability assay, IC50 = 0.67377 μM. | SANGER | ||
| NCI-H1770 | Growth Inhibition Assay | Inhibition of human NCI-H1770 cell growth in a cell viability assay, IC50 = 0.67403 μM. | SANGER | ||
| SW948 | Growth Inhibition Assay | Inhibition of human SW948 cell growth in a cell viability assay, IC50 = 0.6926 μM. | SANGER | ||
| NCI-H2141 | Growth Inhibition Assay | Inhibition of human NCI-H2141 cell growth in a cell viability assay, IC50 = 0.69819 μM. | SANGER | ||
| SK-OV-3 | Growth Inhibition Assay | Inhibition of human SK-OV-3 cell growth in a cell viability assay, IC50 = 0.71264 μM. | SANGER | ||
| GI-1 | Growth Inhibition Assay | Inhibition of human GI-1 cell growth in a cell viability assay, IC50 = 0.72502 μM. | SANGER | ||
| NCI-H2342 | Growth Inhibition Assay | Inhibition of human NCI-H2342 cell growth in a cell viability assay, IC50 = 0.72829 μM. | SANGER | ||
| NB1 | Growth Inhibition Assay | Inhibition of human NB1 cell growth in a cell viability assay, IC50 = 0.73121 μM. | SANGER | ||
| NCI-H1618 | Growth Inhibition Assay | Inhibition of human NCI-H1618 cell growth in a cell viability assay, IC50 = 0.73903 μM. | SANGER | ||
| DMS-273 | Growth Inhibition Assay | Inhibition of human DMS-273 cell growth in a cell viability assay, IC50 = 0.74175 μM. | SANGER | ||
| SW48 | Growth Inhibition Assay | Inhibition of human SW48 cell growth in a cell viability assay, IC50 = 0.74963 μM. | SANGER | ||
| RT-112 | Growth Inhibition Assay | Inhibition of human RT-112 cell growth in a cell viability assay, IC50 = 0.75108 μM. | SANGER | ||
| NCI-H1734 | Growth Inhibition Assay | Inhibition of human NCI-H1734 cell growth in a cell viability assay, IC50 = 0.7629 μM. | SANGER | ||
| SNG-M | Growth Inhibition Assay | Inhibition of human SNG-M cell growth in a cell viability assay, IC50 = 0.78394 μM. | SANGER | ||
| LS-513 | Growth Inhibition Assay | Inhibition of human LS-513 cell growth in a cell viability assay, IC50 = 0.78587 μM. | SANGER | ||
| SCC-4 | Growth Inhibition Assay | Inhibition of human SCC-4 cell growth in a cell viability assay, IC50 = 0.78676 μM. | SANGER | ||
| LCLC-103H | Growth Inhibition Assay | Inhibition of human LCLC-103H cell growth in a cell viability assay, IC50 = 0.78834 μM. | SANGER | ||
| SW954 | Growth Inhibition Assay | Inhibition of human SW954 cell growth in a cell viability assay, IC50 = 0.79303 μM. | SANGER | ||
| COLO-680N | Growth Inhibition Assay | Inhibition of human COLO-680N cell growth in a cell viability assay, IC50 = 0.79945 μM. | SANGER | ||
| NCI-H1651 | Growth Inhibition Assay | Inhibition of human NCI-H1651 cell growth in a cell viability assay, IC50 = 0.80182 μM. | SANGER | ||
| SW620 | Growth Inhibition Assay | Inhibition of human SW620 cell growth in a cell viability assay, IC50 = 0.80713 μM. | SANGER | ||
| KYSE-270 | Growth Inhibition Assay | Inhibition of human KYSE-270 cell growth in a cell viability assay, IC50 = 0.80989 μM. | SANGER | ||
| NCI-H1882 | Growth Inhibition Assay | Inhibition of human NCI-H1882 cell growth in a cell viability assay, IC50 = 0.81014 μM. | SANGER | ||
| YKG-1 | Growth Inhibition Assay | Inhibition of human YKG-1 cell growth in a cell viability assay, IC50 = 0.83103 μM. | SANGER | ||
| A2780 | Growth Inhibition Assay | Inhibition of human A2780 cell growth in a cell viability assay, IC50 = 0.86327 μM. | SANGER | ||
| MES-SA | Growth Inhibition Assay | Inhibition of human MES-SA cell growth in a cell viability assay, IC50 = 0.87372 μM. | SANGER | ||
| BCPAP | Growth Inhibition Assay | Inhibition of human BCPAP cell growth in a cell viability assay, IC50 = 0.87737 μM. | SANGER | ||
| H4 | Growth Inhibition Assay | Inhibition of human H4 cell growth in a cell viability assay, IC50 = 0.90356 μM. | SANGER | ||
| EW-13 | Growth Inhibition Assay | Inhibition of human EW-13 cell growth in a cell viability assay, IC50 = 0.909 μM. | SANGER | ||
| HSC-2 | Growth Inhibition Assay | Inhibition of human HSC-2 cell growth in a cell viability assay, IC50 = 0.91076 μM. | SANGER | ||
| TE-15 | Growth Inhibition Assay | Inhibition of human TE-15 cell growth in a cell viability assay, IC50 = 0.95556 μM. | SANGER | ||
| COR-L23 | Growth Inhibition Assay | Inhibition of human COR-L23 cell growth in a cell viability assay, IC50 = 0.9653 μM. | SANGER | ||
| 786-0 | Growth Inhibition Assay | Inhibition of human 786-0 cell growth in a cell viability assay, IC50 = 0.96904 μM. | SANGER | ||
| A101D | Growth Inhibition Assay | Inhibition of human A101D cell growth in a cell viability assay, IC50 = 0.97646 μM. | SANGER | ||
| G-402 | Growth Inhibition Assay | Inhibition of human G-402 cell growth in a cell viability assay, IC50 = 0.97855 μM. | SANGER | ||
| 639-V | Growth Inhibition Assay | Inhibition of human 639-V cell growth in a cell viability assay, IC50 = 0.99007 μM. | SANGER | ||
| SW872 | Growth Inhibition Assay | Inhibition of human SW872 cell growth in a cell viability assay, IC50 = 0.99324 μM. | SANGER | ||
| MZ2-MEL | Growth Inhibition Assay | Inhibition of human MZ2-MEL cell growth in a cell viability assay, IC50 = 0.99816 μM. | SANGER | ||
| HL-60 | Growth Inhibition Assay | Inhibition of human HL-60 cell growth in a cell viability assay, IC50 = 1.01305 μM. | SANGER | ||
| NCI-H1304 | Growth Inhibition Assay | Inhibition of human NCI-H1304 cell growth in a cell viability assay, IC50 = 1.02172 μM. | SANGER | ||
| GAMG | Growth Inhibition Assay | Inhibition of human GAMG cell growth in a cell viability assay, IC50 = 1.02372 μM. | SANGER | ||
| G-361 | Growth Inhibition Assay | Inhibition of human G-361 cell growth in a cell viability assay, IC50 = 1.03515 μM. | SANGER | ||
| LU-134-A | Growth Inhibition Assay | Inhibition of human LU-134-A cell growth in a cell viability assay, IC50 = 1.04553 μM. | SANGER | ||
| IGR-1 | Growth Inhibition Assay | Inhibition of human IGR-1 cell growth in a cell viability assay, IC50 = 1.06361 μM. | SANGER | ||
| SW962 | Growth Inhibition Assay | Inhibition of human SW962 cell growth in a cell viability assay, IC50 = 1.08487 μM. | SANGER | ||
| KINGS-1 | Growth Inhibition Assay | Inhibition of human KINGS-1 cell growth in a cell viability assay, IC50 = 1.08504 μM. | SANGER | ||
| DEL | Growth Inhibition Assay | Inhibition of human DEL cell growth in a cell viability assay, IC50 = 1.10005 μM. | SANGER | ||
| NB5 | Growth Inhibition Assay | Inhibition of human NB5 cell growth in a cell viability assay, IC50 = 1.11259 μM. | SANGER | ||
| HuCCT1 | Growth Inhibition Assay | Inhibition of human HuCCT1 cell growth in a cell viability assay, IC50 = 1.117 μM. | SANGER | ||
| MS-1 | Growth Inhibition Assay | Inhibition of human MS-1 cell growth in a cell viability assay, IC50 = 1.13564 μM. | SANGER | ||
| CAKI-1 | Growth Inhibition Assay | Inhibition of human CAKI-1 cell growth in a cell viability assay, IC50 = 1.14346 μM. | SANGER | ||
| ATN-1 | Growth Inhibition Assay | Inhibition of human ATN-1 cell growth in a cell viability assay, IC50 = 1.14642 μM. | SANGER | ||
| NCI-H1792 | Growth Inhibition Assay | Inhibition of human NCI-H1792 cell growth in a cell viability assay, IC50 = 1.15225 μM. | SANGER | ||
| NCI-H522 | Growth Inhibition Assay | Inhibition of human NCI-H522 cell growth in a cell viability assay, IC50 = 1.16468 μM. | SANGER | ||
| HOP-62 | Growth Inhibition Assay | Inhibition of human HOP-62 cell growth in a cell viability assay, IC50 = 1.16571 μM. | SANGER | ||
| AGS | Growth Inhibition Assay | Inhibition of human AGS cell growth in a cell viability assay, IC50 = 1.16817 μM. | SANGER | ||
| SW1088 | Growth Inhibition Assay | Inhibition of human SW1088 cell growth in a cell viability assay, IC50 = 1.16879 μM. | SANGER | ||
| COLO-679 | Growth Inhibition Assay | Inhibition of human COLO-679 cell growth in a cell viability assay, IC50 = 1.16945 μM. | SANGER | ||
| PANC-03-27 | Growth Inhibition Assay | Inhibition of human PANC-03-27 cell growth in a cell viability assay, IC50 = 1.17005 μM. | SANGER | ||
| Detroit562 | Growth Inhibition Assay | Inhibition of human Detroit562 cell growth in a cell viability assay, IC50 = 1.1769 μM. | SANGER | ||
| SK-N-FI | Growth Inhibition Assay | Inhibition of human SK-N-FI cell growth in a cell viability assay, IC50 = 1.18752 μM. | SANGER | ||
| SW626 | Growth Inhibition Assay | Inhibition of human SW626 cell growth in a cell viability assay, IC50 = 1.19561 μM. | SANGER | ||
| Daoy | Growth Inhibition Assay | Inhibition of human Daoy cell growth in a cell viability assay, IC50 = 1.20848 μM. | SANGER | ||
| OS-RC-2 | Growth Inhibition Assay | Inhibition of human OS-RC-2 cell growth in a cell viability assay, IC50 = 1.22299 μM. | SANGER | ||
| 8305C | Growth Inhibition Assay | Inhibition of human 8305C cell growth in a cell viability assay, IC50 = 1.23744 μM. | SANGER | ||
| RKO | Growth Inhibition Assay | Inhibition of human RKO cell growth in a cell viability assay, IC50 = 1.24389 μM. | SANGER | ||
| DBTRG-05MG | Growth Inhibition Assay | Inhibition of human DBTRG-05MG cell growth in a cell viability assay, IC50 = 1.26195 μM. | SANGER | ||
| HOS | Growth Inhibition Assay | Inhibition of human HOS cell growth in a cell viability assay, IC50 = 1.27425 μM. | SANGER | ||
| D-542MG | Growth Inhibition Assay | Inhibition of human D-542MG cell growth in a cell viability assay, IC50 = 1.27994 μM. | SANGER | ||
| ST486 | Growth Inhibition Assay | Inhibition of human ST486 cell growth in a cell viability assay, IC50 = 1.28117 μM. | SANGER | ||
| NY | Growth Inhibition Assay | Inhibition of human NY cell growth in a cell viability assay, IC50 = 1.28965 μM. | SANGER | ||
| NCI-H838 | Growth Inhibition Assay | Inhibition of human NCI-H838 cell growth in a cell viability assay, IC50 = 1.2914 μM. | SANGER | ||
| BB65-RCC | Growth Inhibition Assay | Inhibition of human BB65-RCC cell growth in a cell viability assay, IC50 = 1.3022 μM. | SANGER | ||
| MEL-HO | Growth Inhibition Assay | Inhibition of human MEL-HO cell growth in a cell viability assay, IC50 = 1.31336 μM. | SANGER | ||
| HTC-C3 | Growth Inhibition Assay | Inhibition of human HTC-C3 cell growth in a cell viability assay, IC50 = 1.31847 μM. | SANGER | ||
| CAPAN-1 | Growth Inhibition Assay | Inhibition of human CAPAN-1 cell growth in a cell viability assay, IC50 = 1.32561 μM. | SANGER | ||
| SK-UT-1 | Growth Inhibition Assay | Inhibition of human SK-UT-1 cell growth in a cell viability assay, IC50 = 1.32799 μM. | SANGER | ||
| KALS-1 | Growth Inhibition Assay | Inhibition of human KALS-1 cell growth in a cell viability assay, IC50 = 1.32907 μM. | SANGER | ||
| LB831-BLC | Growth Inhibition Assay | Inhibition of human LB831-BLC cell growth in a cell viability assay, IC50 = 1.34639 μM. | SANGER | ||
| KE-37 | Growth Inhibition Assay | Inhibition of human KE-37 cell growth in a cell viability assay, IC50 = 1.35266 μM. | SANGER | ||
| 8505C | Growth Inhibition Assay | Inhibition of human 8505C cell growth in a cell viability assay, IC50 = 1.35994 μM. | SANGER | ||
| BHY | Growth Inhibition Assay | Inhibition of human BHY cell growth in a cell viability assay, IC50 = 1.37413 μM. | SANGER | ||
| ONS-76 | Growth Inhibition Assay | Inhibition of human ONS-76 cell growth in a cell viability assay, IC50 = 1.37892 μM. | SANGER | ||
| BxPC-3 | Growth Inhibition Assay | Inhibition of human BxPC-3 cell growth in a cell viability assay, IC50 = 1.38403 μM. | SANGER | ||
| SK-HEP-1 | Growth Inhibition Assay | Inhibition of human SK-HEP-1 cell growth in a cell viability assay, IC50 = 1.39441 μM. | SANGER | ||
| SK-LMS-1 | Growth Inhibition Assay | Inhibition of human SK-LMS-1 cell growth in a cell viability assay, IC50 = 1.3969 μM. | SANGER | ||
| SNU-423 | Growth Inhibition Assay | Inhibition of human SNU-423 cell growth in a cell viability assay, IC50 = 1.41951 μM. | SANGER | ||
| SF295 | Growth Inhibition Assay | Inhibition of human SF295 cell growth in a cell viability assay, IC50 = 1.43606 μM. | SANGER | ||
| J82 | Growth Inhibition Assay | Inhibition of human J82 cell growth in a cell viability assay, IC50 = 1.43959 μM. | SANGER | ||
| SW837 | Growth Inhibition Assay | Inhibition of human SW837 cell growth in a cell viability assay, IC50 = 1.46365 μM. | SANGER | ||
| TE-9 | Growth Inhibition Assay | Inhibition of human TE-9 cell growth in a cell viability assay, IC50 = 1.47786 μM. | SANGER | ||
| LoVo | Growth Inhibition Assay | Inhibition of human LoVo cell growth in a cell viability assay, IC50 = 1.51747 μM. | SANGER | ||
| NKM-1 | Growth Inhibition Assay | Inhibition of human NKM-1 cell growth in a cell viability assay, IC50 = 1.52468 μM. | SANGER | ||
| A172 | Growth Inhibition Assay | Inhibition of human A172 cell growth in a cell viability assay, IC50 = 1.52721 μM. | SANGER | ||
| A388 | Growth Inhibition Assay | Inhibition of human A388 cell growth in a cell viability assay, IC50 = 1.52944 μM. | SANGER | ||
| TK10 | Growth Inhibition Assay | Inhibition of human TK10 cell growth in a cell viability assay, IC50 = 1.52958 μM. | SANGER | ||
| MPP-89 | Growth Inhibition Assay | Inhibition of human MPP-89 cell growth in a cell viability assay, IC50 = 1.54338 μM. | SANGER | ||
| SF126 | Growth Inhibition Assay | Inhibition of human SF126 cell growth in a cell viability assay, IC50 = 1.55086 μM. | SANGER | ||
| OVCAR-4 | Growth Inhibition Assay | Inhibition of human OVCAR-4 cell growth in a cell viability assay, IC50 = 1.55193 μM. | SANGER | ||
| OCUB-M | Growth Inhibition Assay | Inhibition of human OCUB-M cell growth in a cell viability assay, IC50 = 1.55373 μM. | SANGER | ||
| K5 | Growth Inhibition Assay | Inhibition of human K5 cell growth in a cell viability assay, IC50 = 1.58531 μM. | SANGER | ||
| OE33 | Growth Inhibition Assay | Inhibition of human OE33 cell growth in a cell viability assay, IC50 = 1.59842 μM. | SANGER | ||
| EFO-21 | Growth Inhibition Assay | Inhibition of human EFO-21 cell growth in a cell viability assay, IC50 = 1.60098 μM. | SANGER | ||
| NB13 | Growth Inhibition Assay | Inhibition of human NB13 cell growth in a cell viability assay, IC50 = 1.62119 μM. | SANGER | ||
| SH-4 | Growth Inhibition Assay | Inhibition of human SH-4 cell growth in a cell viability assay, IC50 = 1.62851 μM. | SANGER | ||
| ETK-1 | Growth Inhibition Assay | Inhibition of human ETK-1 cell growth in a cell viability assay, IC50 = 1.6299 μM. | SANGER | ||
| SW1573 | Growth Inhibition Assay | Inhibition of human SW1573 cell growth in a cell viability assay, IC50 = 1.64332 μM. | SANGER | ||
| NCI-H2170 | Growth Inhibition Assay | Inhibition of human NCI-H2170 cell growth in a cell viability assay, IC50 = 1.64499 μM. | SANGER | ||
| NCI-H1417 | Growth Inhibition Assay | Inhibition of human NCI-H1417 cell growth in a cell viability assay, IC50 = 1.67323 μM. | SANGER | ||
| HuO-3N1 | Growth Inhibition Assay | Inhibition of human HuO-3N1 cell growth in a cell viability assay, IC50 = 1.68209 μM. | SANGER | ||
| NCI-H526 | Growth Inhibition Assay | Inhibition of human NCI-H526 cell growth in a cell viability assay, IC50 = 1.69318 μM. | SANGER | ||
| CP66-MEL | Growth Inhibition Assay | Inhibition of human CP66-MEL cell growth in a cell viability assay, IC50 = 1.69608 μM. | SANGER | ||
| LS-123 | Growth Inhibition Assay | Inhibition of human LS-123 cell growth in a cell viability assay, IC50 = 1.69741 μM. | SANGER | ||
| SCC-15 | Growth Inhibition Assay | Inhibition of human SCC-15 cell growth in a cell viability assay, IC50 = 1.70193 μM. | SANGER | ||
| HuP-T4 | Growth Inhibition Assay | Inhibition of human HuP-T4 cell growth in a cell viability assay, IC50 = 1.72836 μM. | SANGER | ||
| HuP-T3 | Growth Inhibition Assay | Inhibition of human HuP-T3 cell growth in a cell viability assay, IC50 = 1.76211 μM. | SANGER | ||
| IST-MES1 | Growth Inhibition Assay | Inhibition of human IST-MES1 cell growth in a cell viability assay, IC50 = 1.76781 μM. | SANGER | ||
| A204 | Growth Inhibition Assay | Inhibition of human A204 cell growth in a cell viability assay, IC50 = 1.77017 μM. | SANGER | ||
| NCI-H2126 | Growth Inhibition Assay | Inhibition of human NCI-H2126 cell growth in a cell viability assay, IC50 = 1.77157 μM. | SANGER | ||
| NCI-H2087 | Growth Inhibition Assay | Inhibition of human NCI-H2087 cell growth in a cell viability assay, IC50 = 1.7974 μM. | SANGER | ||
| SK-MES-1 | Growth Inhibition Assay | Inhibition of human SK-MES-1 cell growth in a cell viability assay, IC50 = 1.80324 μM. | SANGER | ||
| GT3TKB | Growth Inhibition Assay | Inhibition of human GT3TKB cell growth in a cell viability assay, IC50 = 1.80864 μM. | SANGER | ||
| OAW-42 | Growth Inhibition Assay | Inhibition of human OAW-42 cell growth in a cell viability assay, IC50 = 1.85365 μM. | SANGER | ||
| KYSE-410 | Growth Inhibition Assay | Inhibition of human KYSE-410 cell growth in a cell viability assay, IC50 = 1.85455 μM. | SANGER | ||
| NEC8 | Growth Inhibition Assay | Inhibition of human NEC8 cell growth in a cell viability assay, IC50 = 1.85475 μM. | SANGER | ||
| 22RV1 | Growth Inhibition Assay | Inhibition of human 22RV1 cell growth in a cell viability assay, IC50 = 1.85754 μM. | SANGER | ||
| Becker | Growth Inhibition Assay | Inhibition of human Becker cell growth in a cell viability assay, IC50 = 1.86663 μM. | SANGER | ||
| OE19 | Growth Inhibition Assay | Inhibition of human OE19 cell growth in a cell viability assay, IC50 = 1.87707 μM. | SANGER | ||
| ACHN | Growth Inhibition Assay | Inhibition of human ACHN cell growth in a cell viability assay, IC50 = 1.87709 μM. | SANGER | ||
| RXF393 | Growth Inhibition Assay | Inhibition of human RXF393 cell growth in a cell viability assay, IC50 = 1.87802 μM. | SANGER | ||
| NCI-H187 | Growth Inhibition Assay | Inhibition of human NCI-H187 cell growth in a cell viability assay, IC50 = 1.89063 μM. | SANGER | ||
| PC-3 | Growth Inhibition Assay | Inhibition of human PC-3 cell growth in a cell viability assay, IC50 = 1.92634 μM. | SANGER | ||
| DU-145 | Growth Inhibition Assay | Inhibition of human DU-145 cell growth in a cell viability assay, IC50 = 1.92988 μM. | SANGER | ||
| ESS-1 | Growth Inhibition Assay | Inhibition of human ESS-1 cell growth in a cell viability assay, IC50 = 1.9306 μM. | SANGER | ||
| NCI-H716 | Growth Inhibition Assay | Inhibition of human NCI-H716 cell growth in a cell viability assay, IC50 = 1.94349 μM. | SANGER | ||
| SUP-T1 | Growth Inhibition Assay | Inhibition of human SUP-T1 cell growth in a cell viability assay, IC50 = 1.96941 μM. | SANGER | ||
| SNU-449 | Growth Inhibition Assay | Inhibition of human SNU-449 cell growth in a cell viability assay, IC50 = 1.99372 μM. | SANGER | ||
| BEN | Growth Inhibition Assay | Inhibition of human BEN cell growth in a cell viability assay, IC50 = 2.00569 μM. | SANGER | ||
| LB2241-RCC | Growth Inhibition Assay | Inhibition of human LB2241-RCC cell growth in a cell viability assay, IC50 = 2.01324 μM. | SANGER | ||
| MDA-MB-468 | Growth Inhibition Assay | Inhibition of human MDA-MB-468 cell growth in a cell viability assay, IC50 = 2.01868 μM. | SANGER | ||
| 8-MG-BA | Growth Inhibition Assay | Inhibition of human 8-MG-BA cell growth in a cell viability assay, IC50 = 2.01969 μM. | SANGER | ||
| NCI-H2052 | Growth Inhibition Assay | Inhibition of human NCI-H2052 cell growth in a cell viability assay, IC50 = 2.04159 μM. | SANGER | ||
| CAL-120 | Growth Inhibition Assay | Inhibition of human CAL-120 cell growth in a cell viability assay, IC50 = 2.05591 μM. | SANGER | ||
| M059J | Growth Inhibition Assay | Inhibition of human M059J cell growth in a cell viability assay, IC50 = 2.06014 μM. | SANGER | ||
| U-266 | Growth Inhibition Assay | Inhibition of human U-266 cell growth in a cell viability assay, IC50 = 2.06897 μM. | SANGER | ||
| MFE-296 | Growth Inhibition Assay | Inhibition of human MFE-296 cell growth in a cell viability assay, IC50 = 2.07128 μM. | SANGER | ||
| SCC-25 | Growth Inhibition Assay | Inhibition of human SCC-25 cell growth in a cell viability assay, IC50 = 2.08184 μM. | SANGER | ||
| SCLC-21H | Growth Inhibition Assay | Inhibition of human SCLC-21H cell growth in a cell viability assay, IC50 = 2.0999 μM. | SANGER | ||
| A3-KAW | Growth Inhibition Assay | Inhibition of human A3-KAW cell growth in a cell viability assay, IC50 = 2.10206 μM. | SANGER | ||
| KYSE-140 | Growth Inhibition Assay | Inhibition of human KYSE-140 cell growth in a cell viability assay, IC50 = 2.11619 μM. | SANGER | ||
| MEG-01 | Growth Inhibition Assay | Inhibition of human MEG-01 cell growth in a cell viability assay, IC50 = 2.11642 μM. | SANGER | ||
| SK-MEL-30 | Growth Inhibition Assay | Inhibition of human SK-MEL-30 cell growth in a cell viability assay, IC50 = 2.12309 μM. | SANGER | ||
| MONO-MAC-6 | Growth Inhibition Assay | Inhibition of human MONO-MAC-6 cell growth in a cell viability assay, IC50 = 2.13231 μM. | SANGER | ||
| KYSE-450 | Growth Inhibition Assay | Inhibition of human KYSE-450 cell growth in a cell viability assay, IC50 = 2.13843 μM. | SANGER | ||
| NCI-H2009 | Growth Inhibition Assay | Inhibition of human NCI-H2009 cell growth in a cell viability assay, IC50 = 2.14893 μM. | SANGER | ||
| LU-65 | Growth Inhibition Assay | Inhibition of human LU-65 cell growth in a cell viability assay, IC50 = 2.15051 μM. | SANGER | ||
| MHH-NB-11 | Growth Inhibition Assay | Inhibition of human MHH-NB-11 cell growth in a cell viability assay, IC50 = 2.1569 μM. | SANGER | ||
| KYSE-180 | Growth Inhibition Assay | Inhibition of human KYSE-180 cell growth in a cell viability assay, IC50 = 2.16631 μM. | SANGER | ||
| NOMO-1 | Growth Inhibition Assay | Inhibition of human NOMO-1 cell growth in a cell viability assay, IC50 = 2.16852 μM. | SANGER | ||
| ALL-PO | Growth Inhibition Assay | Inhibition of human ALL-PO cell growth in a cell viability assay, IC50 = 2.18649 μM. | SANGER | ||
| CTV-1 | Growth Inhibition Assay | Inhibition of human CTV-1 cell growth in a cell viability assay, IC50 = 2.22588 μM. | SANGER | ||
| KYSE-150 | Growth Inhibition Assay | Inhibition of human KYSE-150 cell growth in a cell viability assay, IC50 = 2.25119 μM. | SANGER | ||
| T-24 | Growth Inhibition Assay | Inhibition of human T-24 cell growth in a cell viability assay, IC50 = 2.25544 μM. | SANGER | ||
| AM-38 | Growth Inhibition Assay | Inhibition of human AM-38 cell growth in a cell viability assay, IC50 = 2.27715 μM. | SANGER | ||
| NCI-H1092 | Growth Inhibition Assay | Inhibition of human NCI-H1092 cell growth in a cell viability assay, IC50 = 2.30326 μM. | SANGER | ||
| SW1783 | Growth Inhibition Assay | Inhibition of human SW1783 cell growth in a cell viability assay, IC50 = 2.3107 μM. | SANGER | ||
| EFE-184 | Growth Inhibition Assay | Inhibition of human EFE-184 cell growth in a cell viability assay, IC50 = 2.3336 μM. | SANGER | ||
| A704 | Growth Inhibition Assay | Inhibition of human A704 cell growth in a cell viability assay, IC50 = 2.345 μM. | SANGER | ||
| COLO-800 | Growth Inhibition Assay | Inhibition of human COLO-800 cell growth in a cell viability assay, IC50 = 2.35695 μM. | SANGER | ||
| DMS-153 | Growth Inhibition Assay | Inhibition of human DMS-153 cell growth in a cell viability assay, IC50 = 2.38808 μM. | SANGER | ||
| TGW | Growth Inhibition Assay | Inhibition of human TGW cell growth in a cell viability assay, IC50 = 2.40252 μM. | SANGER | ||
| U031 | Growth Inhibition Assay | Inhibition of human U031 cell growth in a cell viability assay, IC50 = 2.41075 μM. | SANGER | ||
| ACN | Growth Inhibition Assay | Inhibition of human ACN cell growth in a cell viability assay, IC50 = 2.45048 μM. | SANGER | ||
| KP-N-YN | Growth Inhibition Assay | Inhibition of human KP-N-YN cell growth in a cell viability assay, IC50 = 2.46004 μM. | SANGER | ||
| EGI-1 | Growth Inhibition Assay | Inhibition of human EGI-1 cell growth in a cell viability assay, IC50 = 2.49591 μM. | SANGER | ||
| UMC-11 | Growth Inhibition Assay | Inhibition of human UMC-11 cell growth in a cell viability assay, IC50 = 2.51219 μM. | SANGER | ||
| SK-N-AS | Growth Inhibition Assay | Inhibition of human SK-N-AS cell growth in a cell viability assay, IC50 = 2.54232 μM. | SANGER | ||
| SF268 | Growth Inhibition Assay | Inhibition of human SF268 cell growth in a cell viability assay, IC50 = 2.55044 μM. | SANGER | ||
| KARPAS-45 | Growth Inhibition Assay | Inhibition of human KARPAS-45 cell growth in a cell viability assay, IC50 = 2.56467 μM. | SANGER | ||
| VMRC-RCZ | Growth Inhibition Assay | Inhibition of human VMRC-RCZ cell growth in a cell viability assay, IC50 = 2.57247 μM. | SANGER | ||
| NCCIT | Growth Inhibition Assay | Inhibition of human NCCIT cell growth in a cell viability assay, IC50 = 2.60543 μM. | SANGER | ||
| HOP-92 | Growth Inhibition Assay | Inhibition of human HOP-92 cell growth in a cell viability assay, IC50 = 2.61037 μM. | SANGER | ||
| MDA-MB-231 | Growth Inhibition Assay | Inhibition of human MDA-MB-231 cell growth in a cell viability assay, IC50 = 2.61419 μM. | SANGER | ||
| NB6 | Growth Inhibition Assay | Inhibition of human NB6 cell growth in a cell viability assay, IC50 = 2.62328 μM. | SANGER | ||
| CAL-62 | Growth Inhibition Assay | Inhibition of human CAL-62 cell growth in a cell viability assay, IC50 = 2.66243 μM. | SANGER | ||
| HO-1-N-1 | Growth Inhibition Assay | Inhibition of human HO-1-N-1 cell growth in a cell viability assay, IC50 = 2.66336 μM. | SANGER | ||
| NCI-H2405 | Growth Inhibition Assay | Inhibition of human NCI-H2405 cell growth in a cell viability assay, IC50 = 2.68417 μM. | SANGER | ||
| MKN28 | Growth Inhibition Assay | Inhibition of human MKN28 cell growth in a cell viability assay, IC50 = 2.69293 μM. | SANGER | ||
| HAL-01 | Growth Inhibition Assay | Inhibition of human HAL-01 cell growth in a cell viability assay, IC50 = 2.74249 μM. | SANGER | ||
| COLO-824 | Growth Inhibition Assay | Inhibition of human COLO-824 cell growth in a cell viability assay, IC50 = 2.76602 μM. | SANGER | ||
| HT-1080 | Growth Inhibition Assay | Inhibition of human HT-1080 cell growth in a cell viability assay, IC50 = 2.76838 μM. | SANGER | ||
| NCI-H226 | Growth Inhibition Assay | Inhibition of human NCI-H226 cell growth in a cell viability assay, IC50 = 2.80694 μM. | SANGER | ||
| BFTC-909 | Growth Inhibition Assay | Inhibition of human BFTC-909 cell growth in a cell viability assay, IC50 = 2.88386 μM. | SANGER | ||
| LB2518-MEL | Growth Inhibition Assay | Inhibition of human LB2518-MEL cell growth in a cell viability assay, IC50 = 2.92298 μM. | SANGER | ||
| HC-1 | Growth Inhibition Assay | Inhibition of human HC-1 cell growth in a cell viability assay, IC50 = 2.92852 μM. | SANGER | ||
| NCI-H661 | Growth Inhibition Assay | Inhibition of human NCI-H661 cell growth in a cell viability assay, IC50 = 3.01168 μM. | SANGER | ||
| DoTc2-4510 | Growth Inhibition Assay | Inhibition of human DoTc2-4510 cell growth in a cell viability assay, IC50 = 3.1079 μM. | SANGER | ||
| KG-1 | Growth Inhibition Assay | Inhibition of human KG-1 cell growth in a cell viability assay, IC50 = 3.1079 μM. | SANGER | ||
| OAW-28 | Growth Inhibition Assay | Inhibition of human OAW-28 cell growth in a cell viability assay, IC50 = 3.11075 μM. | SANGER | ||
| VM-CUB-1 | Growth Inhibition Assay | Inhibition of human VM-CUB-1 cell growth in a cell viability assay, IC50 = 3.13715 μM. | SANGER | ||
| HCC1569 | Growth Inhibition Assay | Inhibition of human HCC1569 cell growth in a cell viability assay, IC50 = 3.16762 μM. | SANGER | ||
| MMAC-SF | Growth Inhibition Assay | Inhibition of human MMAC-SF cell growth in a cell viability assay, IC50 = 3.1697 μM. | SANGER | ||
| RERF-LC-MS | Growth Inhibition Assay | Inhibition of human RERF-LC-MS cell growth in a cell viability assay, IC50 = 3.17549 μM. | SANGER | ||
| HCT-116 | Growth Inhibition Assay | Inhibition of human HCT-116 cell growth in a cell viability assay, IC50 = 3.20817 μM. | SANGER | ||
| C-4-II | Growth Inhibition Assay | Inhibition of human C-4-II cell growth in a cell viability assay, IC50 = 3.25771 μM. | SANGER | ||
| GMS-10 | Growth Inhibition Assay | Inhibition of human GMS-10 cell growth in a cell viability assay, IC50 = 3.31731 μM. | SANGER | ||
| OVCAR-8 | Growth Inhibition Assay | Inhibition of human OVCAR-8 cell growth in a cell viability assay, IC50 = 3.34206 μM. | SANGER | ||
| HLE | Growth Inhibition Assay | Inhibition of human HLE cell growth in a cell viability assay, IC50 = 3.34577 μM. | SANGER | ||
| CHL-1 | Growth Inhibition Assay | Inhibition of human CHL-1 cell growth in a cell viability assay, IC50 = 3.34883 μM. | SANGER | ||
| NCI-H2030 | Growth Inhibition Assay | Inhibition of human NCI-H2030 cell growth in a cell viability assay, IC50 = 3.37653 μM. | SANGER | ||
| ES7 | Growth Inhibition Assay | Inhibition of human ES7 cell growth in a cell viability assay, IC50 = 3.39911 μM. | SANGER | ||
| GOTO | Growth Inhibition Assay | Inhibition of human GOTO cell growth in a cell viability assay, IC50 = 3.41732 μM. | SANGER | ||
| NCI-H1623 | Growth Inhibition Assay | Inhibition of human NCI-H1623 cell growth in a cell viability assay, IC50 = 3.42053 μM. | SANGER | ||
| COLO-678 | Growth Inhibition Assay | Inhibition of human COLO-678 cell growth in a cell viability assay, IC50 = 3.44564 μM. | SANGER | ||
| Ca-Ski | Growth Inhibition Assay | Inhibition of human Ca-Ski cell growth in a cell viability assay, IC50 = 3.46887 μM. | SANGER | ||
| EW-3 | Growth Inhibition Assay | Inhibition of human EW-3 cell growth in a cell viability assay, IC50 = 3.51436 μM. | SANGER | ||
| LOXIMVI | Growth Inhibition Assay | Inhibition of human LOXIMVI cell growth in a cell viability assay, IC50 = 3.51627 μM. | SANGER | ||
| LC4-1 | Growth Inhibition Assay | Inhibition of human LC4-1 cell growth in a cell viability assay, IC50 = 3.55663 μM. | SANGER | ||
| CTB-1 | Growth Inhibition Assay | Inhibition of human CTB-1 cell growth in a cell viability assay, IC50 = 3.56175 μM. | SANGER | ||
| ChaGo-K-1 | Growth Inhibition Assay | Inhibition of human ChaGo-K-1 cell growth in a cell viability assay, IC50 = 3.58434 μM. | SANGER | ||
| NCI-H1581 | Growth Inhibition Assay | Inhibition of human NCI-H1581 cell growth in a cell viability assay, IC50 = 3.64943 μM. | SANGER | ||
| HT-3 | Growth Inhibition Assay | Inhibition of human HT-3 cell growth in a cell viability assay, IC50 = 3.66857 μM. | SANGER | ||
| DV-90 | Growth Inhibition Assay | Inhibition of human DV-90 cell growth in a cell viability assay, IC50 = 3.67678 μM. | SANGER | ||
| MRK-nu-1 | Growth Inhibition Assay | Inhibition of human MRK-nu-1 cell growth in a cell viability assay, IC50 = 3.70735 μM. | SANGER | ||
| RPMI-8402 | Growth Inhibition Assay | Inhibition of human RPMI-8402 cell growth in a cell viability assay, IC50 = 3.71196 μM. | SANGER | ||
| HCE-T | Growth Inhibition Assay | Inhibition of human HCE-T cell growth in a cell viability assay, IC50 = 3.71981 μM. | SANGER | ||
| BPH-1 | Growth Inhibition Assay | Inhibition of human BPH-1 cell growth in a cell viability assay, IC50 = 3.8199 μM. | SANGER | ||
| D-263MG | Growth Inhibition Assay | Inhibition of human D-263MG cell growth in a cell viability assay, IC50 = 3.84417 μM. | SANGER | ||
| U-118-MG | Growth Inhibition Assay | Inhibition of human U-118-MG cell growth in a cell viability assay, IC50 = 4.02428 μM. | SANGER | ||
| SN12C | Growth Inhibition Assay | Inhibition of human SN12C cell growth in a cell viability assay, IC50 = 4.04292 μM. | SANGER | ||
| KURAMOCHI | Growth Inhibition Assay | Inhibition of human KURAMOCHI cell growth in a cell viability assay, IC50 = 4.05467 μM. | SANGER | ||
| COLO-829 | Growth Inhibition Assay | Inhibition of human COLO-829 cell growth in a cell viability assay, IC50 = 4.1346 μM. | SANGER | ||
| GR-ST | Growth Inhibition Assay | Inhibition of human GR-ST cell growth in a cell viability assay, IC50 = 4.17635 μM. | SANGER | ||
| NCI-H2081 | Growth Inhibition Assay | Inhibition of human NCI-H2081 cell growth in a cell viability assay, IC50 = 4.28007 μM. | SANGER | ||
| KNS-81-FD | Growth Inhibition Assay | Inhibition of human KNS-81-FD cell growth in a cell viability assay, IC50 = 4.40655 μM. | SANGER | ||
| Calu-6 | Growth Inhibition Assay | Inhibition of human Calu-6 cell growth in a cell viability assay, IC50 = 4.41101 μM. | SANGER | ||
| U251 | Growth Inhibition Assay | Inhibition of human U251 cell growth in a cell viability assay, IC50 = 4.44884 μM. | SANGER | ||
| KP-4 | Growth Inhibition Assay | Inhibition of human KP-4 cell growth in a cell viability assay, IC50 = 4.49305 μM. | SANGER | ||
| HuH-7 | Growth Inhibition Assay | Inhibition of human HuH-7 cell growth in a cell viability assay, IC50 = 4.49657 μM. | SANGER | ||
| NCI-H2347 | Growth Inhibition Assay | Inhibition of human NCI-H2347 cell growth in a cell viability assay, IC50 = 4.5022 μM. | SANGER | ||
| SK-MEL-24 | Growth Inhibition Assay | Inhibition of human SK-MEL-24 cell growth in a cell viability assay, IC50 = 4.53506 μM. | SANGER | ||
| HEL | Growth Inhibition Assay | Inhibition of human HEL cell growth in a cell viability assay, IC50 = 4.54405 μM. | SANGER | ||
| NCI-H460 | Growth Inhibition Assay | Inhibition of human NCI-H460 cell growth in a cell viability assay, IC50 = 4.5776 μM. | SANGER | ||
| CA46 | Growth Inhibition Assay | Inhibition of human CA46 cell growth in a cell viability assay, IC50 = 4.59584 μM. | SANGER | ||
| NCI-H1755 | Growth Inhibition Assay | Inhibition of human NCI-H1755 cell growth in a cell viability assay, IC50 = 4.62915 μM. | SANGER | ||
| CESS | Growth Inhibition Assay | Inhibition of human CESS cell growth in a cell viability assay, IC50 = 4.65205 μM. | SANGER | ||
| MHH-CALL-2 | Growth Inhibition Assay | Inhibition of human MHH-CALL-2 cell growth in a cell viability assay, IC50 = 4.68861 μM. | SANGER | ||
| UM-UC-3 | Growth Inhibition Assay | Inhibition of human UM-UC-3 cell growth in a cell viability assay, IC50 = 4.71548 μM. | SANGER | ||
| LXF-289 | Growth Inhibition Assay | Inhibition of human LXF-289 cell growth in a cell viability assay, IC50 = 4.74443 μM. | SANGER | ||
| T47D | Growth Inhibition Assay | Inhibition of human T47D cell growth in a cell viability assay, IC50 = 4.76635 μM. | SANGER | ||
| TE-6 | Growth Inhibition Assay | Inhibition of human TE-6 cell growth in a cell viability assay, IC50 = 4.81703 μM. | SANGER | ||
| ECC4 | Growth Inhibition Assay | Inhibition of human ECC4 cell growth in a cell viability assay, IC50 = 4.83833 μM. | SANGER | ||
| CAL-33 | Growth Inhibition Assay | Inhibition of human CAL-33 cell growth in a cell viability assay, IC50 = 4.84825 μM. | SANGER | ||
| SW13 | Growth Inhibition Assay | Inhibition of human SW13 cell growth in a cell viability assay, IC50 = 4.87146 μM. | SANGER | ||
| 769-P | Growth Inhibition Assay | Inhibition of human 769-P cell growth in a cell viability assay, IC50 = 4.88193 μM. | SANGER | ||
| U-2-OS | Growth Inhibition Assay | Inhibition of human U-2-OS cell growth in a cell viability assay, IC50 = 4.90779 μM. | SANGER | ||
| LAMA-84 | Growth Inhibition Assay | Inhibition of human LAMA-84 cell growth in a cell viability assay, IC50 = 4.92749 μM. | SANGER | ||
| NCI-H345 | Growth Inhibition Assay | Inhibition of human NCI-H345 cell growth in a cell viability assay, IC50 = 4.96365 μM. | SANGER | ||
| NCI-H1694 | Growth Inhibition Assay | Inhibition of human NCI-H1694 cell growth in a cell viability assay, IC50 = 4.96855 μM. | SANGER | ||
| C2BBe1 | Growth Inhibition Assay | Inhibition of human C2BBe1 cell growth in a cell viability assay, IC50 = 4.98155 μM. | SANGER | ||
| COLO-684 | Growth Inhibition Assay | Inhibition of human COLO-684 cell growth in a cell viability assay, IC50 = 5.06788 μM. | SANGER | ||
| LC-1F | Growth Inhibition Assay | Inhibition of human LC-1F cell growth in a cell viability assay, IC50 = 5.0921 μM. | SANGER | ||
| A2058 | Growth Inhibition Assay | Inhibition of human A2058 cell growth in a cell viability assay, IC50 = 5.26272 μM. | SANGER | ||
| MOLT-16 | Growth Inhibition Assay | Inhibition of human MOLT-16 cell growth in a cell viability assay, IC50 = 5.32484 μM. | SANGER | ||
| DU-4475 | Growth Inhibition Assay | Inhibition of human DU-4475 cell growth in a cell viability assay, IC50 = 5.36197 μM. | SANGER | ||
| SNU-C2B | Growth Inhibition Assay | Inhibition of human SNU-C2B cell growth in a cell viability assay, IC50 = 5.44771 μM. | SANGER | ||
| TUR | Growth Inhibition Assay | Inhibition of human TUR cell growth in a cell viability assay, IC50 = 5.51595 μM. | SANGER | ||
| Daudi | Growth Inhibition Assay | Inhibition of human Daudi cell growth in a cell viability assay, IC50 = 5.51694 μM. | SANGER | ||
| IMR-5 | Growth Inhibition Assay | Inhibition of human IMR-5 cell growth in a cell viability assay, IC50 = 5.6021 μM. | SANGER | ||
| IST-MEL1 | Growth Inhibition Assay | Inhibition of human IST-MEL1 cell growth in a cell viability assay, IC50 = 5.63247 μM. | SANGER | ||
| NCI-H1650 | Growth Inhibition Assay | Inhibition of human NCI-H1650 cell growth in a cell viability assay, IC50 = 5.64209 μM. | SANGER | ||
| LOUCY | Growth Inhibition Assay | Inhibition of human LOUCY cell growth in a cell viability assay, IC50 = 5.66174 μM. | SANGER | ||
| NCI-H1963 | Growth Inhibition Assay | Inhibition of human NCI-H1963 cell growth in a cell viability assay, IC50 = 5.66692 μM. | SANGER | ||
| KMOE-2 | Growth Inhibition Assay | Inhibition of human KMOE-2 cell growth in a cell viability assay, IC50 = 5.7626 μM. | SANGER | ||
| HCE-4 | Growth Inhibition Assay | Inhibition of human HCE-4 cell growth in a cell viability assay, IC50 = 5.78117 μM. | SANGER | ||
| SF539 | Growth Inhibition Assay | Inhibition of human SF539 cell growth in a cell viability assay, IC50 = 5.81309 μM. | SANGER | ||
| GCT | Growth Inhibition Assay | Inhibition of human GCT cell growth in a cell viability assay, IC50 = 5.99711 μM. | SANGER | ||
| BHT-101 | Growth Inhibition Assay | Inhibition of human BHT-101 cell growth in a cell viability assay, IC50 = 6.0215 μM. | SANGER | ||
| MV-4-11 | Growth Inhibition Assay | Inhibition of human MV-4-11 cell growth in a cell viability assay, IC50 = 6.10704 μM. | SANGER | ||
| D-283MED | Growth Inhibition Assay | Inhibition of human D-283MED cell growth in a cell viability assay, IC50 = 6.17633 μM. | SANGER | ||
| HH | Growth Inhibition Assay | Inhibition of human HH cell growth in a cell viability assay, IC50 = 6.20084 μM. | SANGER | ||
| IA-LM | Growth Inhibition Assay | Inhibition of human IA-LM cell growth in a cell viability assay, IC50 = 6.23432 μM. | SANGER | ||
| LP-1 | Growth Inhibition Assay | Inhibition of human LP-1 cell growth in a cell viability assay, IC50 = 6.27356 μM. | SANGER | ||
| QIMR-WIL | Growth Inhibition Assay | Inhibition of human QIMR-WIL cell growth in a cell viability assay, IC50 = 6.29707 μM. | SANGER | ||
| M14 | Growth Inhibition Assay | Inhibition of human M14 cell growth in a cell viability assay, IC50 = 6.58861 μM. | SANGER | ||
| HT-1376 | Growth Inhibition Assay | Inhibition of human HT-1376 cell growth in a cell viability assay, IC50 = 6.62249 μM. | SANGER | ||
| RPMI-7951 | Growth Inhibition Assay | Inhibition of human RPMI-7951 cell growth in a cell viability assay, IC50 = 6.64003 μM. | SANGER | ||
| NCI-H1563 | Growth Inhibition Assay | Inhibition of human NCI-H1563 cell growth in a cell viability assay, IC50 = 6.64282 μM. | SANGER | ||
| Ca9-22 | Growth Inhibition Assay | Inhibition of human Ca9-22 cell growth in a cell viability assay, IC50 = 6.6908 μM. | SANGER | ||
| NCI-H2227 | Growth Inhibition Assay | Inhibition of human NCI-H2227 cell growth in a cell viability assay, IC50 = 6.72244 μM. | SANGER | ||
| L-540 | Growth Inhibition Assay | Inhibition of human L-540 cell growth in a cell viability assay, IC50 = 6.97353 μM. | SANGER | ||
| NALM-6 | Growth Inhibition Assay | Inhibition of human NALM-6 cell growth in a cell viability assay, IC50 = 7.12163 μM. | SANGER | ||
| HCC1143 | Growth Inhibition Assay | Inhibition of human HCC1143 cell growth in a cell viability assay, IC50 = 7.1789 μM. | SANGER | ||
| CAL-54 | Growth Inhibition Assay | Inhibition of human CAL-54 cell growth in a cell viability assay, IC50 = 7.30834 μM. | SANGER | ||
| CAS-1 | Growth Inhibition Assay | Inhibition of human CAS-1 cell growth in a cell viability assay, IC50 = 7.37047 μM. | SANGER | ||
| RCC10RGB | Growth Inhibition Assay | Inhibition of human RCC10RGB cell growth in a cell viability assay, IC50 = 7.54014 μM. | SANGER | ||
| NCI-H1573 | Growth Inhibition Assay | Inhibition of human NCI-H1573 cell growth in a cell viability assay, IC50 = 7.56522 μM. | SANGER | ||
| 697 | Growth Inhibition Assay | Inhibition of human 697 cell growth in a cell viability assay, IC50 = 7.58666 μM. | SANGER | ||
| LNCaP-Clone-FGC | Growth Inhibition Assay | Inhibition of human LNCaP-Clone-FGC cell growth in a cell viability assay, IC50 = 7.85618 μM. | SANGER | ||
| HT55 | Growth Inhibition Assay | Inhibition of human HT55 cell growth in a cell viability assay, IC50 = 8.02849 μM. | SANGER | ||
| KARPAS-422 | Growth Inhibition Assay | Inhibition of human KARPAS-422 cell growth in a cell viability assay, IC50 = 8.03517 μM. | SANGER | ||
| BT-20 | Growth Inhibition Assay | Inhibition of human BT-20 cell growth in a cell viability assay, IC50 = 8.42844 μM. | SANGER | ||
| MDA-MB-361 | Growth Inhibition Assay | Inhibition of human MDA-MB-361 cell growth in a cell viability assay, IC50 = 8.54339 μM. | SANGER | ||
| DMS-114 | Growth Inhibition Assay | Inhibition of human DMS-114 cell growth in a cell viability assay, IC50 = 8.66749 μM. | SANGER | ||
| EoL-1-cell | Growth Inhibition Assay | Inhibition of human EoL-1-cell cell growth in a cell viability assay, IC50 = 8.66955 μM. | SANGER | ||
| NB12 | Growth Inhibition Assay | Inhibition of human NB12 cell growth in a cell viability assay, IC50 = 8.86699 μM. | SANGER | ||
| HDLM-2 | Growth Inhibition Assay | Inhibition of human HDLM-2 cell growth in a cell viability assay, IC50 = 9.16845 μM. | SANGER | ||
| ME-180 | Growth Inhibition Assay | Inhibition of human ME-180 cell growth in a cell viability assay, IC50 = 9.25521 μM. | SANGER | ||
| PFSK-1 | Growth Inhibition Assay | Inhibition of human PFSK-1 cell growth in a cell viability assay, IC50 = 9.38893 μM. | SANGER | ||
| NCI-H1522 | Growth Inhibition Assay | Inhibition of human NCI-H1522 cell growth in a cell viability assay, IC50 = 9.63917 μM. | SANGER | ||
| SR | Growth Inhibition Assay | Inhibition of human SR cell growth in a cell viability assay, IC50 = 9.8234 μM. | SANGER | ||
| LU-165 | Growth Inhibition Assay | Inhibition of human LU-165 cell growth in a cell viability assay, IC50 = 9.835 μM. | SANGER | ||
| EB2 | Growth Inhibition Assay | Inhibition of human EB2 cell growth in a cell viability assay, IC50 = 9.8583 μM. | SANGER | ||
| C3A | Growth Inhibition Assay | Inhibition of human C3A cell growth in a cell viability assay, IC50 = 9.87709 μM. | SANGER | ||
| NCI-H1793 | Growth Inhibition Assay | Inhibition of human NCI-H1793 cell growth in a cell viability assay, IC50 = 9.90289 μM. | SANGER | ||
| NCI-H28 | Growth Inhibition Assay | Inhibition of human NCI-H28 cell growth in a cell viability assay, IC50 = 10.1407 μM. | SANGER | ||
| UACC-257 | Growth Inhibition Assay | Inhibition of human UACC-257 cell growth in a cell viability assay, IC50 = 10.4166 μM. | SANGER | ||
| MDA-MB-134-VI | Growth Inhibition Assay | Inhibition of human MDA-MB-134-VI cell growth in a cell viability assay, IC50 = 10.6056 μM. | SANGER | ||
| IST-SL2 | Growth Inhibition Assay | Inhibition of human IST-SL2 cell growth in a cell viability assay, IC50 = 10.6583 μM. | SANGER | ||
| CGTH-W-1 | Growth Inhibition Assay | Inhibition of human CGTH-W-1 cell growth in a cell viability assay, IC50 = 10.7825 μM. | SANGER | ||
| C-33-A | Growth Inhibition Assay | Inhibition of human C-33-A cell growth in a cell viability assay, IC50 = 10.7975 μM. | SANGER | ||
| Hs-578-T | Growth Inhibition Assay | Inhibition of human Hs-578-T cell growth in a cell viability assay, IC50 = 10.8458 μM. | SANGER | ||
| MZ7-mel | Growth Inhibition Assay | Inhibition of human MZ7-mel cell growth in a cell viability assay, IC50 = 11.0898 μM. | SANGER | ||
| KP-N-YS | Growth Inhibition Assay | Inhibition of human KP-N-YS cell growth in a cell viability assay, IC50 = 11.4914 μM. | SANGER | ||
| LB373-MEL-D | Growth Inhibition Assay | Inhibition of human LB373-MEL-D cell growth in a cell viability assay, IC50 = 11.8696 μM. | SANGER | ||
| NCI-H520 | Growth Inhibition Assay | Inhibition of human NCI-H520 cell growth in a cell viability assay, IC50 = 11.9407 μM. | SANGER | ||
| CAL-148 | Growth Inhibition Assay | Inhibition of human CAL-148 cell growth in a cell viability assay, IC50 = 12.0776 μM. | SANGER | ||
| KYSE-70 | Growth Inhibition Assay | Inhibition of human KYSE-70 cell growth in a cell viability assay, IC50 = 12.1046 μM. | SANGER | ||
| OVCAR-3 | Growth Inhibition Assay | Inhibition of human OVCAR-3 cell growth in a cell viability assay, IC50 = 12.1331 μM. | SANGER | ||
| SBC-1 | Growth Inhibition Assay | Inhibition of human SBC-1 cell growth in a cell viability assay, IC50 = 12.1884 μM. | SANGER | ||
| NCI-H1993 | Growth Inhibition Assay | Inhibition of human NCI-H1993 cell growth in a cell viability assay, IC50 = 12.2994 μM. | SANGER | ||
| Calu-1 | Growth Inhibition Assay | Inhibition of human Calu-1 cell growth in a cell viability assay, IC50 = 12.3415 μM. | SANGER | ||
| WSU-NHL | Growth Inhibition Assay | Inhibition of human WSU-NHL cell growth in a cell viability assay, IC50 = 12.3788 μM. | SANGER | ||
| J-RT3-T3-5 | Growth Inhibition Assay | Inhibition of human J-RT3-T3-5 cell growth in a cell viability assay, IC50 = 12.4848 μM. | SANGER | ||
| PA-1 | Growth Inhibition Assay | Inhibition of human PA-1 cell growth in a cell viability assay, IC50 = 12.5451 μM. | SANGER | ||
| IM-9 | Growth Inhibition Assay | Inhibition of human IM-9 cell growth in a cell viability assay, IC50 = 12.7138 μM. | SANGER | ||
| KM-H2 | Growth Inhibition Assay | Inhibition of human KM-H2 cell growth in a cell viability assay, IC50 = 12.7654 μM. | SANGER | ||
| U-87-MG | Growth Inhibition Assay | Inhibition of human U-87-MG cell growth in a cell viability assay, IC50 = 13.0415 μM. | SANGER | ||
| HPAF-II | Growth Inhibition Assay | Inhibition of human HPAF-II cell growth in a cell viability assay, IC50 = 13.4808 μM. | SANGER | ||
| DB | Growth Inhibition Assay | Inhibition of human DB cell growth in a cell viability assay, IC50 = 13.7045 μM. | SANGER | ||
| BOKU | Growth Inhibition Assay | Inhibition of human BOKU cell growth in a cell viability assay, IC50 = 13.8328 μM. | SANGER | ||
| HCC38 | Growth Inhibition Assay | Inhibition of human HCC38 cell growth in a cell viability assay, IC50 = 13.8335 μM. | SANGER | ||
| MDA-MB-157 | Growth Inhibition Assay | Inhibition of human MDA-MB-157 cell growth in a cell viability assay, IC50 = 13.9601 μM. | SANGER | ||
| FTC-133 | Growth Inhibition Assay | Inhibition of human FTC-133 cell growth in a cell viability assay, IC50 = 14.139 μM. | SANGER | ||
| MC-CAR | Growth Inhibition Assay | Inhibition of human MC-CAR cell growth in a cell viability assay, IC50 = 14.5038 μM. | SANGER | ||
| THP-1 | Growth Inhibition Assay | Inhibition of human THP-1 cell growth in a cell viability assay, IC50 = 14.614 μM. | SANGER | ||
| HCT-15 | Growth Inhibition Assay | Inhibition of human HCT-15 cell growth in a cell viability assay, IC50 = 14.7066 μM. | SANGER | ||
| NCI-H1155 | Growth Inhibition Assay | Inhibition of human NCI-H1155 cell growth in a cell viability assay, IC50 = 14.7657 μM. | SANGER | ||
| D-392MG | Growth Inhibition Assay | Inhibition of human D-392MG cell growth in a cell viability assay, IC50 = 15.198 μM. | SANGER | ||
| HT-1197 | Growth Inhibition Assay | Inhibition of human HT-1197 cell growth in a cell viability assay, IC50 = 15.2627 μM. | SANGER | ||
| T98G | Growth Inhibition Assay | Inhibition of human T98G cell growth in a cell viability assay, IC50 = 16.2469 μM. | SANGER | ||
| BC-3 | Growth Inhibition Assay | Inhibition of human BC-3 cell growth in a cell viability assay, IC50 = 16.3723 μM. | SANGER | ||
| DMS-53 | Growth Inhibition Assay | Inhibition of human DMS-53 cell growth in a cell viability assay, IC50 = 16.4241 μM. | SANGER | ||
| PC-14 | Growth Inhibition Assay | Inhibition of human PC-14 cell growth in a cell viability assay, IC50 = 16.496 μM. | SANGER | ||
| NCI-H1703 | Growth Inhibition Assay | Inhibition of human NCI-H1703 cell growth in a cell viability assay, IC50 = 16.5926 μM. | SANGER | ||
| ARH-77 | Growth Inhibition Assay | Inhibition of human ARH-77 cell growth in a cell viability assay, IC50 = 16.9307 μM. | SANGER | ||
| NCI-H1436 | Growth Inhibition Assay | Inhibition of human NCI-H1436 cell growth in a cell viability assay, IC50 = 17.2361 μM. | SANGER | ||
| RCM-1 | Growth Inhibition Assay | Inhibition of human RCM-1 cell growth in a cell viability assay, IC50 = 17.9934 μM. | SANGER | ||
| CAL-72 | Growth Inhibition Assay | Inhibition of human CAL-72 cell growth in a cell viability assay, IC50 = 18.1382 μM. | SANGER | ||
| JiyoyeP-2003 | Growth Inhibition Assay | Inhibition of human JiyoyeP-2003 cell growth in a cell viability assay, IC50 = 18.3276 μM. | SANGER | ||
| AsPC-1 | Growth Inhibition Assay | Inhibition of human AsPC-1 cell growth in a cell viability assay, IC50 = 18.8638 μM. | SANGER | ||
| OCI-AML2 | Growth Inhibition Assay | Inhibition of human OCI-AML2 cell growth in a cell viability assay, IC50 = 19.0924 μM. | SANGER | ||
| RO82-W-1 | Growth Inhibition Assay | Inhibition of human RO82-W-1 cell growth in a cell viability assay, IC50 = 19.2558 μM. | SANGER | ||
| NCI-H209 | Growth Inhibition Assay | Inhibition of human NCI-H209 cell growth in a cell viability assay, IC50 = 19.2741 μM. | SANGER | ||
| RPMI-6666 | Growth Inhibition Assay | Inhibition of human RPMI-6666 cell growth in a cell viability assay, IC50 = 19.3018 μM. | SANGER | ||
| P30-OHK | Growth Inhibition Assay | Inhibition of human P30-OHK cell growth in a cell viability assay, IC50 = 19.6604 μM. | SANGER | ||
| SW1990 | Growth Inhibition Assay | Inhibition of human SW1990 cell growth in a cell viability assay, IC50 = 19.7833 μM. | SANGER | ||
| A498 | Growth Inhibition Assay | Inhibition of human A498 cell growth in a cell viability assay, IC50 = 20.0041 μM. | SANGER | ||
| Calu-3 | Growth Inhibition Assay | Inhibition of human Calu-3 cell growth in a cell viability assay, IC50 = 20.0694 μM. | SANGER | ||
| SW1463 | Growth Inhibition Assay | Inhibition of human SW1463 cell growth in a cell viability assay, IC50 = 20.0705 μM. | SANGER | ||
| YT | Growth Inhibition Assay | Inhibition of human YT cell growth in a cell viability assay, IC50 = 20.687 μM. | SANGER | ||
| MDA-MB-175-VII | Growth Inhibition Assay | Inhibition of human MDA-MB-175-VII cell growth in a cell viability assay, IC50 = 20.7094 μM. | SANGER | ||
| NUGC-3 | Growth Inhibition Assay | Inhibition of human NUGC-3 cell growth in a cell viability assay, IC50 = 20.8286 μM. | SANGER | ||
| COLO-792 | Growth Inhibition Assay | Inhibition of human COLO-792 cell growth in a cell viability assay, IC50 = 20.8786 μM. | SANGER | ||
| NCI-H748 | Growth Inhibition Assay | Inhibition of human NCI-H748 cell growth in a cell viability assay, IC50 = 20.9574 μM. | SANGER | ||
| SW1417 | Growth Inhibition Assay | Inhibition of human SW1417 cell growth in a cell viability assay, IC50 = 21.0448 μM. | SANGER | ||
| REH | Growth Inhibition Assay | Inhibition of human REH cell growth in a cell viability assay, IC50 = 21.0864 μM. | SANGER | ||
| HEC-1 | Growth Inhibition Assay | Inhibition of human HEC-1 cell growth in a cell viability assay, IC50 = 21.8654 μM. | SANGER | ||
| no-10 | Growth Inhibition Assay | Inhibition of human no-10 cell growth in a cell viability assay, IC50 = 22.6912 μM. | SANGER | ||
| EM-2 | Growth Inhibition Assay | Inhibition of human EM-2 cell growth in a cell viability assay, IC50 = 23.3021 μM. | SANGER | ||
| LN-405 | Growth Inhibition Assay | Inhibition of human LN-405 cell growth in a cell viability assay, IC50 = 23.4328 μM. | SANGER | ||
| RVH-421 | Growth Inhibition Assay | Inhibition of human RVH-421 cell growth in a cell viability assay, IC50 = 23.6492 μM. | SANGER | ||
| CAMA-1 | Growth Inhibition Assay | Inhibition of human CAMA-1 cell growth in a cell viability assay, IC50 = 24.0797 μM. | SANGER | ||
| MDA-MB-453 | Growth Inhibition Assay | Inhibition of human MDA-MB-453 cell growth in a cell viability assay, IC50 = 24.4188 μM. | SANGER | ||
| EFO-27 | Growth Inhibition Assay | Inhibition of human EFO-27 cell growth in a cell viability assay, IC50 = 24.4381 μM. | SANGER | ||
| LU-139 | Growth Inhibition Assay | Inhibition of human LU-139 cell growth in a cell viability assay, IC50 = 24.4583 μM. | SANGER | ||
| YAPC | Growth Inhibition Assay | Inhibition of human YAPC cell growth in a cell viability assay, IC50 = 25.4403 μM. | SANGER | ||
| CCRF-CEM | Growth Inhibition Assay | Inhibition of human CCRF-CEM cell growth in a cell viability assay, IC50 = 25.4533 μM. | SANGER | ||
| DJM-1 | Growth Inhibition Assay | Inhibition of human DJM-1 cell growth in a cell viability assay, IC50 = 26.0811 μM. | SANGER | ||
| SNU-475 | Growth Inhibition Assay | Inhibition of human SNU-475 cell growth in a cell viability assay, IC50 = 26.345 μM. | SANGER | ||
| Ramos-2G6-4C10 | Growth Inhibition Assay | Inhibition of human Ramos-2G6-4C10 cell growth in a cell viability assay, IC50 = 26.4762 μM. | SANGER | ||
| HCC1187 | Growth Inhibition Assay | Inhibition of human HCC1187 cell growth in a cell viability assay, IC50 = 26.7959 μM. | SANGER | ||
| EFM-19 | Growth Inhibition Assay | Inhibition of human EFM-19 cell growth in a cell viability assay, IC50 = 26.8204 μM. | SANGER | ||
| HT | Growth Inhibition Assay | Inhibition of human HT cell growth in a cell viability assay, IC50 = 27.169 μM. | SANGER | ||
| NCI-H64 | Growth Inhibition Assay | Inhibition of human NCI-H64 cell growth in a cell viability assay, IC50 = 28.2381 μM. | SANGER | ||
| JEG-3 | Growth Inhibition Assay | Inhibition of human JEG-3 cell growth in a cell viability assay, IC50 = 28.3241 μM. | SANGER | ||
| CAL-27 | Growth Inhibition Assay | Inhibition of human CAL-27 cell growth in a cell viability assay, IC50 = 28.4822 μM. | SANGER | ||
| HSC-4 | Growth Inhibition Assay | Inhibition of human HSC-4 cell growth in a cell viability assay, IC50 = 28.7306 μM. | SANGER | ||
| HCC1599 | Growth Inhibition Assay | Inhibition of human HCC1599 cell growth in a cell viability assay, IC50 = 29.235 μM. | SANGER | ||
| TE-5 | Growth Inhibition Assay | Inhibition of human TE-5 cell growth in a cell viability assay, IC50 = 30.5378 μM. | SANGER | ||
| IPC-298 | Growth Inhibition Assay | Inhibition of human IPC-298 cell growth in a cell viability assay, IC50 = 30.9652 μM. | SANGER | ||
| EHEB | Growth Inhibition Assay | Inhibition of human EHEB cell growth in a cell viability assay, IC50 = 31.1889 μM. | SANGER | ||
| NCI-H322M | Growth Inhibition Assay | Inhibition of human NCI-H322M cell growth in a cell viability assay, IC50 = 33.5237 μM. | SANGER | ||
| A253 | Growth Inhibition Assay | Inhibition of human A253 cell growth in a cell viability assay, IC50 = 34.0349 μM. | SANGER | ||
| NCI-H596 | Growth Inhibition Assay | Inhibition of human NCI-H596 cell growth in a cell viability assay, IC50 = 34.8541 μM. | SANGER | ||
| MN-60 | Growth Inhibition Assay | Inhibition of human MN-60 cell growth in a cell viability assay, IC50 = 35.9922 μM. | SANGER | ||
| C32 | Growth Inhibition Assay | Inhibition of human C32 cell growth in a cell viability assay, IC50 = 37.6212 μM. | SANGER | ||
| SCC-9 | Growth Inhibition Assay | Inhibition of human SCC-9 cell growth in a cell viability assay, IC50 = 37.8733 μM. | SANGER | ||
| COR-L279 | Growth Inhibition Assay | Inhibition of human COR-L279 cell growth in a cell viability assay, IC50 = 37.9052 μM. | SANGER | ||
| MOLT-4 | Growth Inhibition Assay | Inhibition of human MOLT-4 cell growth in a cell viability assay, IC50 = 38.4987 μM. | SANGER | ||
| RT4 | Growth Inhibition Assay | Inhibition of human RT4 cell growth in a cell viability assay, IC50 = 39.105 μM. | SANGER | ||
| MLMA | Growth Inhibition Assay | Inhibition of human MLMA cell growth in a cell viability assay, IC50 = 39.1717 μM. | SANGER | ||
| KYSE-520 | Growth Inhibition Assay | Inhibition of human KYSE-520 cell growth in a cell viability assay, IC50 = 39.3112 μM. | SANGER | ||
| NCI-H2196 | Growth Inhibition Assay | Inhibition of human NCI-H2196 cell growth in a cell viability assay, IC50 = 40.0071 μM. | SANGER | ||
| MKN1 | Growth Inhibition Assay | Inhibition of human MKN1 cell growth in a cell viability assay, IC50 = 40.2345 μM. | SANGER | ||
| HN | Growth Inhibition Assay | Inhibition of human HN cell growth in a cell viability assay, IC50 = 40.5211 μM. | SANGER | ||
| MFE-280 | Growth Inhibition Assay | Inhibition of human MFE-280 cell growth in a cell viability assay, IC50 = 41.3794 μM. | SANGER | ||
| 647-V | Growth Inhibition Assay | Inhibition of human 647-V cell growth in a cell viability assay, IC50 = 41.8832 μM. | SANGER | ||
| PF-382 | Growth Inhibition Assay | Inhibition of human PF-382 cell growth in a cell viability assay, IC50 = 42.0242 μM. | SANGER | ||
| IST-SL1 | Growth Inhibition Assay | Inhibition of human IST-SL1 cell growth in a cell viability assay, IC50 = 42.3247 μM. | SANGER | ||
| MKN7 | Growth Inhibition Assay | Inhibition of human MKN7 cell growth in a cell viability assay, IC50 = 42.4977 μM. | SANGER | ||
| CP50-MEL-B | Growth Inhibition Assay | Inhibition of human CP50-MEL-B cell growth in a cell viability assay, IC50 = 42.6901 μM. | SANGER | ||
| K052 | Growth Inhibition Assay | Inhibition of human K052 cell growth in a cell viability assay, IC50 = 43.0698 μM. | SANGER | ||
| 23132-87 | Growth Inhibition Assay | Inhibition of human 23132-87 cell growth in a cell viability assay, IC50 = 43.5286 μM. | SANGER | ||
| GAK | Growth Inhibition Assay | Inhibition of human GAK cell growth in a cell viability assay, IC50 = 44.127 μM. | SANGER | ||
| Mewo | Growth Inhibition Assay | Inhibition of human Mewo cell growth in a cell viability assay, IC50 = 45.5878 μM. | SANGER | ||
| RMG-I | Growth Inhibition Assay | Inhibition of human RMG-I cell growth in a cell viability assay, IC50 = 45.7372 μM. | SANGER | ||
| BE-13 | Growth Inhibition Assay | Inhibition of human BE-13 cell growth in a cell viability assay, IC50 = 45.9392 μM. | SANGER | ||
| SW684 | Growth Inhibition Assay | Inhibition of human SW684 cell growth in a cell viability assay, IC50 = 47.4969 μM. | SANGER | ||
| 他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい | |||||
生物活性
| 製品説明 | BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met (c-Met), Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2. | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 特性 | Muti-inhibitor of the IGR-1R/IR family. | |||||||||||
| Targets |
|
| In Vitro | ||||
| In vitro |
BMS-754807 effectively inhibits the growth of a broad range of human tumor cell lines of different histologic origins including mesenchymal (Ewing's, rhabdomyosarcoma, neuroblastoma, and liposarcoma), epithelial (breast, lung, pancreatic, colon, and gastric), and hematopoietic (multiple myeloma and leukemia), the IC50 values range from 5 nM to 365 nM for the most sensitive cell lines. BMS-754807 inhibits proliferation of IGF-1R-Sal cells and RH41 cells with IC50 of 7 nM and 5 nM. BMS-754807 inhibits phosphorylation of IGF-1R in IGF-1R-Sal cells, Rh41 and Geo with IC50 of 13 nM, 6 nM and 21 nM. BMS-754807 inhibits phosphorylation of Akt in IGF-1R-Sal cells, Rh41 and Geo with IC50 of 22 nM, 13 nM and 16 nM. BMS-754807 induces greater apoptosis in Rh41 cells by 24 hours as indicated by an increased sub-G1 peak (23.1%), compared with control (2.4%). [1] BMS-754807 inhibits the phosphorylation of IGF-1R (IC50 = 13nM) and the downstream targets Akt (IC50 = 22nM) and MAPK (IC50 = 13nM) in the IGF-Sal cell line with IC50 consistent with the antiproliferative IC50 (7 nM) in this cell line. The crystal structure of BMS-754807 cocrystallized with the kinase domain of IGF-1R shows that the donor/acceptor/donor hydrogen bond triad with Met1052 and Glu1050 within the hinge region of the kinase. [2] BMS-754807 shows a median EC50 value of 0.62 μM against 23 cell lines in the pediatric preclinical testing program (PPTP). [3] |
|||
|---|---|---|---|---|
| Kinase Assay | Kinase inhibition assays | |||
| The primary screen for BMS-754807 is an in vitro kinase assay using recombinant human IGF-1 receptor enzyme in biochemical assays using synthetic peptide KKSRGDYMTMQIG as a phosphoacceptor substrate. The selectivity profile is evaluated against multiple recombinant enzymes that are generated at BMS or purchased externally. The enzymatic assays are performed in Ubottom 384-well plates using a 30 μL reaction volume in assay buffer (100 mM Hepes pH 7.4, 10 mM MgCl2, 0.015% Brij35 and 4 mM DTT). The 60 minute reactions are initiated by combining ATP (concentration equivalent to Km ATP), 1.5 μM labeled peptide substrate, enzyme and BMS-754807. The reactions are terminated with EDTA. The reaction mixtures are analyzed on the Caliper LabChip 3000 by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data are calculated by comparison to enzyme-free control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. Compounds are dissolved in DMSO, 10mM stock and evaluated at eleven concentrations. IC50 values are derived by non-linear regression analysis of the dose response curves. | ||||
| 細胞実験 | 細胞株 | IGF-1R-Sal, RH41 and Geo cell lines | ||
| 濃度 | 365 nM | |||
| 反応時間 | 72 hours | |||
| 実験の流れ | Cells are grown at their optimal density in RPMI +GlutaMax supplemented with 10% heat-inactivated fetal bovine serum (FBS). Cell proliferation is evaluated by incorporation of 3H-thymidine into DNA after exposure of cells to BMS-754807 for 72 hours. Results are expressed as an IC50, which is the drug concentration required to inhibit cell proliferation by 50% compared with untreated control cells. |
|||
| 実験結果図 | Methods | Biomarkers | 結果図 | PMID |
| Growth inhibition assay | Cell viability |
|
30754629 | |
| Western blot | p-IGFIRRβ/InsRβ / IGFIRβ / p-AKT / AKT / p-ERK / ERK |
|
26136493 | |
| In Vivo | ||
| In Vivo |
BMS-754807 (12.5mg/kg, orally) inhibits IGF-1R phosphorylation in tumor and serum in IGF-1R-Sal tumor–bearing nude mice. BMS-754807 inhibits tumor growth in a selected group of epithelial (IGF-1R-Sal, GEO, and Colo205), hematopoietic (JJN3), and mesenchymal (RD1 and Rh41) xenograft tumor models with TGI ranging from 53% to 115%. [1] BMS-754807 (6.25 mg/kg) achieves complete tumor growth inhibition in the transgenic-derived IGF-Sal tumor mouse model with correlated inhibition of pIGF-1R and pAKT. The protein binding for BMS-754807 ranges from of 98.5% in mouse plasma to 95.9% in human plasma. BMS-754807 results in clearance of 113 (mL/min)/kg, 20 (mL/min)/kg, 3.5 (mL/min)/kg and 41 (mL/min)/kg. [2] BMS-754807 (25 mg/kg) significantly inhibits tumor in KT-5 (Wilms), KT-14 (rhabdoid), Rh28 (rhabdomyosarcoma), and OS-1 xenografts mice model. [3] |
|
|---|---|---|
| 動物実験 | 動物モデル | IGF-1R-Sal, GEO, Colo205, JJN3, RD1 or Rh41 tumor–bearing nude mice |
| 投与量 | 150 mg/kg | |
| 投与経路 | Orally | |
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT01525823 | Completed | Healthy Volunteers |
Bristol-Myers Squibb |
February 2012 | Phase 1 |
| NCT00908024 | Terminated | Colorectal Cancer|Head and Neck Cancer|Neoplasm Metastasis |
Bristol-Myers Squibb |
October 2009 | Phase 1|Phase 2 |
| NCT00898716 | Completed | Neoplasms |
Bristol-Myers Squibb |
September 2009 | Phase 1 |
| NCT00788333 | Completed | Breast Cancer |
Bristol-Myers Squibb |
July 2009 | Phase 1|Phase 2 |
化学情報
| 分子量 | 461.49 | 化学式 | C23H24FN9O |
| CAS No. | 1001350-96-4 | SDF | Download BMS-754807 SDFをダウンロードする |
| Smiles | CC1(CCCN1C2=NN3C=CC=C3C(=N2)NC4=NNC(=C4)C5CC5)C(=O)NC6=CN=C(C=C6)F | ||
| 保管 | |||
|
In vitro |
DMSO : 92 mg/mL ( (199.35 mM)； 吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。) Ethanol : 92 mg/mL Water : Insoluble |
モル濃度計算器 |
|
in vivo Add solvents to the product individually and in order. |
投与溶液組成計算機 | ||||
実験計算
投与溶液組成計算機(クリア溶液)
ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）
mg/kg
g
μL
匹
ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
計算結果：
投与溶媒濃度： mg/ml;
DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )
投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH2O，を加え完全に溶解させます。
投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。
注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。
技術サポート
ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。
他に質問がある場合は、お気軽にお問い合わせください。
* 必須
Tags: BMS-754807を買う | BMS-754807 ic50 | BMS-754807供給者 | BMS-754807を購入する | BMS-754807費用 | BMS-754807生産者 | オーダーBMS-754807 | BMS-754807化学構造 | BMS-754807分子量 | BMS-754807代理店
納期 国内在庫品：受注日の翌日（15時までの受注分） ＊北海道、九州、沖縄への配送は受注日より２日以上 を要する場合あり 海外在庫品：受注後１〜２週間